[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 154
1. Yiğitler C, Ataç K, Yiğit T, Güleç B, Balkan M, Oner K: [A rare cause of bleeding intestinal intussusception in adult: jejunal lipoma]. Ulus Travma Acil Cerrahi Derg; 2007 Jul;13(3):237-40
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A rare cause of bleeding intestinal intussusception in adult: jejunal lipoma].
  • [Transliterated title] Erişkinde nadir bir intestinal intussusepsiyon ve kanama nedeni: Jejunal lipom.
  • Small bowel neoplasms are usually diagnosed when patients are referred with complications such as hemorrhage or obstruction.
  • Intestinal lipomas are the third most frequent benign tumors among all intestinal neoplasms and their definite diagnosis is usually obtained after histopathological examination of the resected specimen.
  • A 76 year-old male patient with partial intestinal obstruction and rectal bleeding at admittance was found to have an abdominal mass on ultrasound.
  • The diagnosis of lipoma was confirmed with histopathological examination of the mass removed by an elective intestinal resection.
  • This case was reported as the intestinal lipoma leading a jejunojejunal intussusception associated with bleeding, could be diagnosed preoperatively.
  • [MeSH-major] Gastrointestinal Hemorrhage / etiology. Intussusception / diagnosis. Intussusception / etiology. Jejunal Neoplasms / diagnosis. Lipoma / diagnosis

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17978901.001).
  • [ISSN] 1306-696X
  • [Journal-full-title] Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES
  • [ISO-abbreviation] Ulus Travma Acil Cerrahi Derg
  • [Language] tur
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


2. Ahlquist T, Lind GE, Costa VL, Meling GI, Vatn M, Hoff GS, Rognum TO, Skotheim RI, Thiis-Evensen E, Lothe RA: Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer; 2008;7:94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers.
  • BACKGROUND: Multiple epigenetic and genetic changes have been reported in colorectal tumors, but few of these have clinical impact.
  • This study aims to pinpoint epigenetic markers that can discriminate between non-malignant and malignant tissue from the large bowel, i.e. markers with diagnostic potential.
  • Possible CIMP tumors were identified by comparing the methylation profile with microsatellite instability (MSI), BRAF-, KRAS-, and TP53 mutation status.
  • RESULTS: The mean number of methylated genes per sample was 0.4 in normal colon mucosa from tumor-free individuals, 1.2 in mucosa from cancerous bowels, 2.2 in adenomas, and 3.9 in carcinomas.
  • The promoters of ADAMTS1, MAL, and MGMT were frequently methylated in benign samples as well as in malignant tumors, independent of microsatellite instability.
  • In contrast, normal mucosa samples taken from bowels without tumor were rarely methylated for the same genes.
  • CONCLUSION: Methylated ADAMTS1, MGMT, and MAL are suitable as markers for early tumor detection.
  • [MeSH-major] Biomarkers, Tumor / analysis. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. DNA Methylation. Early Detection of Cancer. Genes, Neoplasm. Intestinal Mucosa / metabolism
  • [MeSH-minor] Adenoma / genetics. Adult. Aged. Aged, 80 and over. Cluster Analysis. DNA, Neoplasm / metabolism. Epigenesis, Genetic. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Microsatellite Instability. Microsatellite Repeats / genetics. Middle Aged. Promoter Regions, Genetic. Sex Characteristics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9107-16 [17909015.001]
  • [Cites] PLoS Genet. 2007 Sep;3(9):1709-23 [17892325.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18654-9 [18003927.001]
  • [Cites] Surg Oncol. 2007 Dec;16 Suppl 1:S7-9 [18023574.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2429-36 [18240147.001]
  • [Cites] J Transl Med. 2008;6:13 [18346269.001]
  • [Cites] J Korean Med Sci. 2008 Apr;23(2):270-7 [18437011.001]
  • [Cites] Oncol Rep. 2008 Jun;19(6):1571-6 [18497967.001]
  • [Cites] Eur J Cancer. 2008 Jun;44(9):1290-301 [18486467.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Dig Liver Dis. 2001 May;33(4):372-88 [11432519.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):799-803 [11440966.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9796-801 [11481438.001]
  • [Cites] Neoplasia. 2008 Jul;10(7):680-6, 2 p following 686 [18592002.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):136-42 [18542073.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):795-800 [11891178.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):285-91 [11896207.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1823-30 [12000733.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:101-28 [12142355.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):815-22 [12598316.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):820-9 [12610180.001]
  • [Cites] Acta Neuropathol. 2003 Nov;106(5):479-85 [12904991.001]
  • [Cites] Lancet. 2004 Apr 17;363(9417):1283-5 [15094274.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3014-21 [15126336.001]
  • [Cites] Histol Histopathol. 2004 Jul;19(3):925-33 [15168355.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 9;319(4):1327-33 [15194513.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):884-93 [15122305.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Oct;41(2):117-24 [15287024.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 18;96(16):1208-19 [15316056.001]
  • [Cites] Int J Cancer. 2004 Nov 10;112(3):407-10 [15382065.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):846-53 [15386372.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):754-9 [15386381.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Apr;84(7):1997-2001 [3494249.001]
  • [Cites] Br J Cancer. 1991 Sep;64(3):475-80 [1911187.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5489-94 [9850084.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Scand J Gastroenterol. 1999 Apr;34(4):414-20 [10365903.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [10411935.001]
  • [Cites] Mol Cancer. 2004 Oct 11;3:28 [15476557.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1203-9 [15709190.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32 [16077070.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1317-9 [16174847.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1330-8 [16174854.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2274-9 [16181380.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):771-8 [16207479.001]
  • [Cites] Carcinogenesis. 2005 Dec;26(12):2078-85 [16033773.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):924-31 [16108009.001]
  • [Cites] Genome Res. 2006 Feb;16(2):282-9 [16369045.001]
  • [Cites] Br J Cancer. 2006 Feb 27;94(4):593-8 [16421593.001]
  • [Cites] Diagn Mol Pathol. 2006 Mar;15(1):17-23 [16531764.001]
  • [Cites] Nat Genet. 2006 May;38(5):540-9 [16642018.001]
  • [Cites] Pathol Res Pract. 2006;202(6):415-24 [16675157.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] Oncol Rep. 2006 Aug;16(2):429-35 [16820927.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Aug;21(8):1334-9 [16872319.001]
  • [Cites] Gut. 2006 Oct;55(10):1467-74 [16469793.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10664-70 [17090521.001]
  • [Cites] Cell Oncol. 2006;28(5-6):247-57 [17167178.001]
  • [Cites] Cell Oncol. 2006;28(5-6):259-72 [17167179.001]
  • [Cites] Hum Genet. 2007 Jan;120(5):701-11 [17024368.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):127-38 [17087942.001]
  • [Cites] World J Gastroenterol. 2007 Feb 14;13(6):950-4 [17352030.001]
  • [Cites] Crit Rev Oncog. 2006 Dec;12(3-4):273-87 [17425506.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1631-2; author reply 1632 [17408629.001]
  • [Cites] Oncol Rep. 2007 Jun;17(6):1421-7 [17487400.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5048-55 [17785556.001]
  • (PMID = 19117505.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2639620
  •  go-up   go-down


3. Hart WR: Borderline epithelial tumors of the ovary. Mod Pathol; 2005 Feb;18 Suppl 2:S33-50
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Borderline epithelial tumors of the ovary.
  • The concept and terminology of borderline epithelial tumors of the ovary have been controversial for over a century, in spite of the acceptance of a borderline category in almost all current classifications of ovarian tumors.
  • Typically, borderline tumors are noninvasive neoplasms that have nuclear abnormalities and mitotic activity intermediate between benign and malignant tumors of similar cell type.
  • Borderline tumors of all surface epithelial cell types have been studied.
  • The most common and best understood are serous borderline tumors and mucinous borderline tumors of intestinal type, which are the subject of this review.
  • Some of the most challenging issues for serous tumors include: the criteria and clinical behavior of stromal microinvasion; the high prevalence of synchronous extraovarian disease; the classification and histopathologic features of associated peritoneal tumor implants, especially invasive implants; and, the prognostic significance of micropapillary tumors.
  • The mucinous borderline tumors of intestinal type have a different set of considerations, including: their frequently heterogeneous composition with coexisting benign, borderline and malignant elements; the classification and significance of accompanying noninvasive carcinoma; the recognition of stromal invasion, including microinvasion and expansile invasion; and, the historically misunderstood relationship to pseudomyxoma peritonei.
  • All of these issues are discussed in this presentation, as are the important gross and microscopic features of serous and mucinous borderline tumors and pertinent information on their treatment and prognosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15761465.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 93
  •  go-up   go-down


Advertisement
4. Groen EJ, Roos A, Muntinghe FL, Enting RH, de Vries J, Kleibeuker JH, Witjes MJ, Links TP, van Beek AP: Extra-intestinal manifestations of familial adenomatous polyposis. Ann Surg Oncol; 2008 Sep;15(9):2439-50
Genetic Alliance. consumer health - Familial Polyposis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extra-intestinal manifestations of familial adenomatous polyposis.
  • Familial adenomatous polyposis (FAP) is an autosomal dominantly inherited disorder, which results from a germ line mutation in the APC (adenomatous polyposis coli) gene.
  • Although the development of colorectal cancer stands out as the most prevalent complication, FAP is a multisystem disorder of growth.
  • Thus, clinicians that care for and counsel members of high-risk families should have familiarity with all the extra-intestinal manifestations of this syndrome.
  • Affected individuals can develop thyroid and pancreatic cancer, hepatoblastomas, CNS tumors (especially medulloblastomas), and various benign tumors such as adrenal adenomas, osteomas, desmoid tumors and dental abnormalities.
  • We present a clinical overview of extra-intestinal manifestations, including management and treatment options for the FAP syndrome.
  • [MeSH-major] Adenomatous Polyposis Coli / diagnosis. Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 May;18(9):1967-79 [10784639.001]
  • [Cites] Mayo Clin Proc. 2000 Jun;75(6):636-7 [10852426.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21 Suppl):81S-92S [11060333.001]
  • [Cites] Dis Colon Rectum. 2000 Dec;43(12):1739-42 [11156460.001]
  • [Cites] Dis Colon Rectum. 2000 Dec;43(12):1759-62; discussion 1762-3 [11156464.001]
  • [Cites] Endocr Res. 2000 Nov;26(4):783-90 [11196455.001]
  • [Cites] Int J Cancer. 2001 Mar 20;95(2):102-7 [11241320.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):721-33 [11257105.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):429-32 [11283619.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2744-58 [9215849.001]
  • [Cites] AJR Am J Roentgenol. 1997 Aug;169(2):465-72 [9242755.001]
  • [Cites] Intern Med. 1997 Aug;36(8):536-42 [9260769.001]
  • [Cites] Int J Colorectal Dis. 1997;12(4):240-2 [9272455.001]
  • [Cites] Dis Colon Rectum. 1997 Sep;40(9):1023-8 [9293929.001]
  • [Cites] Gut. 1997 Sep;41(3):417 [9378405.001]
  • [Cites] Int J Cancer. 1998 Jan 5;75(1):162-4 [9426707.001]
  • [Cites] Ann Surg. 1998 Jan;227(1):57-62 [9445111.001]
  • [Cites] Hum Pathol. 1998 Mar;29(3):302-6 [9496836.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):286-92 [10634400.001]
  • [Cites] Scand J Gastroenterol. 1999 Dec;34(12):1230-5 [10636071.001]
  • [Cites] Science. 2000 Mar 3;287(5458):1606-9 [10733430.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):433-8 [11283620.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):332-9 [11466687.001]
  • [Cites] Gastroenterology. 2001 Nov;121(5):1127-35 [11677205.001]
  • [Cites] Am J Gastroenterol. 2002 Jan;97(1):180-5 [11808944.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):55-67 [11900252.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):1941-6 [11994321.001]
  • [Cites] Gut. 2002 Sep;51(3):446-9 [12171972.001]
  • [Cites] Ann Intern Med. 2003 Mar 4;138(5):424-9 [12614096.001]
  • [Cites] Gut. 2003 May;52(5):742-6 [12692062.001]
  • [Cites] Acta Radiol. 2003 Mar;44(2):158-9 [12694100.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1698-707 [12721244.001]
  • [Cites] Lancet. 2003 May 3;361(9368):1552-4 [12737880.001]
  • [Cites] Lancet. 2003 Jun 14;361(9374):2059-67 [12814730.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):668-78 [12910509.001]
  • [Cites] Eur J Cancer. 2003 Oct;39(15):2200-4 [14522379.001]
  • [Cites] Fam Cancer. 2001;1(2):111-9 [14574007.001]
  • [Cites] Gastroenterol Clin Biol. 2003 Aug-Sep;27(8-9):818-20 [14586255.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):612-20 [14745880.001]
  • [Cites] Semin Neonatol. 2003 Oct;8(5):403-10 [15001128.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):652; author reply 653 [15274082.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):666-75 [15497120.001]
  • [Cites] Australas Ann Med. 1967 Aug;16(3):242-4 [6056613.001]
  • [Cites] Clin Genet. 1981 Jul;20(1):67-73 [7296952.001]
  • [Cites] Cancer. 1983 Mar 15;51(6):1171-5 [6129922.001]
  • [Cites] Arch Dis Child. 1983 Dec;58(12):959-62 [6318669.001]
  • [Cites] Cancer. 1985 May 1;55(9):2001-4 [3978580.001]
  • [Cites] Dis Colon Rectum. 1986 Jan;29(1):55-8 [3940808.001]
  • [Cites] N Engl J Med. 1987 Mar 12;316(11):661-7 [3821797.001]
  • [Cites] Br J Surg. 1987 May;74(5):377-80 [3036290.001]
  • [Cites] Acta Chir Scand. 1987;153(5-6):379-83 [2821714.001]
  • [Cites] Med Pediatr Oncol. 1989;17(5):441-7 [2571918.001]
  • [Cites] J Craniomaxillofac Surg. 1989 Nov;17(8):350-3 [2592575.001]
  • [Cites] J Pediatr. 1991 Nov;119(5):766-8 [1658283.001]
  • [Cites] Surgery. 1991 Dec;110(6):1014-21 [1745970.001]
  • [Cites] Hum Genet. 1992 May;89(3):298-300 [1351034.001]
  • [Cites] Am J Med Genet. 1992 Aug 1;43(6):1023-5 [1329510.001]
  • [Cites] Ann Surg. 1993 Feb;217(2):101-8 [8382467.001]
  • [Cites] Int J Oral Maxillofac Surg. 1993 Aug;22(4):226-30 [8409564.001]
  • [Cites] Dis Colon Rectum. 1993 Nov;36(11):1059-62 [8223060.001]
  • [Cites] Gastroenterology. 1993 Nov;105(5):1550-2 [8224661.001]
  • [Cites] Gut. 1993 Oct;34(10):1394-6 [8244108.001]
  • [Cites] Gut. 1994 Mar;35(3):377-81 [8150351.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2065-8 [8156512.001]
  • [Cites] Hum Mutat. 1994;3(2):121-5 [8199592.001]
  • [Cites] J Clin Pathol. 1994 Sep;47(9):860-1 [7962661.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] AJR Am J Roentgenol. 1995 Dec;165(6):1460-1 [7484586.001]
  • [Cites] Int J Colorectal Dis. 1996;11(2):88-91 [8739833.001]
  • [Cites] Lancet. 1996 Aug 17;348(9025):433-5 [8709782.001]
  • [Cites] Int J Colorectal Dis. 1996;11(4):157-62 [8876270.001]
  • [Cites] Cancer. 1996 Dec 1;78(11):2400-10 [8941012.001]
  • [Cites] Br J Surg. 1996 Nov;83(11):1494-504 [9014661.001]
  • [Cites] Gut. 1996 Dec;39(6):867-9 [9038672.001]
  • [Cites] Am J Med Genet. 1997 Mar 31;69(3):299-308 [9096761.001]
  • [Cites] Chirurgie. 1997;122(1):31-4 [9183898.001]
  • [Cites] World J Surg. 1998 Dec;22(12):1231-6 [9841749.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):1007-14 [9869223.001]
  • [Cites] J Med Genet. 1999 Jan;36(1):65-7 [9950370.001]
  • [Cites] Ann Surg. 1999 Mar;229(3):350-61 [10077047.001]
  • [Cites] Dis Colon Rectum. 1999 Apr;42(4):529-32 [10215057.001]
  • [Cites] Am J Pathol. 1999 Jul;155(1):7-9 [10393829.001]
  • [Cites] Br J Surg. 1999 Sep;86(9):1185-9 [10504375.001]
  • [Cites] Am J Hum Genet. 1952 Mar;4(1):31-6 [14933371.001]
  • [Cites] Am J Hum Genet. 1953 Jun;5(2):139-47 [13065261.001]
  • [Cites] Dis Colon Rectum. 1959 Sep-Oct;2:465-8 [13839882.001]
  • [Cites] J Clin Pathol. 2005 Jan;58(1):97-101 [15623495.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1642-54 [15887156.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):273-80 [15947102.001]
  • [Cites] Fam Cancer. 2005;4(2):135-8 [15951964.001]
  • [Cites] Lancet. 2005 Jun 11-17;365(9476):2014-23 [15950715.001]
  • [Cites] J Pediatr. 2005 Aug;147(2):263-6 [16126064.001]
  • [Cites] Ned Tijdschr Tandheelkd. 2005 Sep;112(9):340-4 [16184913.001]
  • [Cites] Arch Pathol Lab Med. 2005 Nov;129(11):1398-400 [16253018.001]
  • [Cites] Pancreas. 2005 Nov;31(4):428-9 [16258383.001]
  • [Cites] Radiology. 2005 Dec;237(3):794-800 [16304103.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):385-98 [16454848.001]
  • [Cites] Gastrointest Endosc. 2006 Apr;63(4):570-80 [16564854.001]
  • [Cites] Thyroid. 2006 Feb;16(2):109-42 [16420177.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-81; quiz 665 [16682259.001]
  • [Cites] Pediatr Blood Cancer. 2006 Nov;47(6):851-4 [16106429.001]
  • [Cites] Pediatr Blood Cancer. 2006 Nov;47(6):811-8 [16317745.001]
  • [Cites] Fam Cancer. 2006;5(3):263-73 [16998672.001]
  • [Cites] Br J Surg. 2006 Oct;93(10):1258-64 [16952208.001]
  • [Cites] Horm Res. 2006;66(5):207-10 [16865001.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jun;103(6):e30-4 [17449294.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Feb;6(2):215-9 [18237870.001]
  • [CommentIn] Ann Surg Oncol. 2009 May;16(5):1446-8; author reply 1449-50 [19266242.001]
  • (PMID = 18612695.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein
  • [Number-of-references] 111
  • [Other-IDs] NLM/ PMC2518080
  •  go-up   go-down


5. Yimyaem P, Saranrittichai S, Sinawat P, Dhiensiri T: Inflammatory myofibroblastic tumor of the small intestine: a case report of a 2 month-old infant. J Med Assoc Thai; 2009 Jan;92(1):114-9
MedlinePlus Health Information. consumer health - Small Intestine Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor of the small intestine: a case report of a 2 month-old infant.
  • Benign intestinal tumors are rare in children; however, the authors describe an inflammatory myofibroblastic tumor (IMT) of the terminal ileum in a 2-month-old infant who presented with an intestinal obstruction.
  • A review of the literature for this rare condition was done to delineate the natural history of this tumor and to do a histological confirmation of its benign nature.
  • [MeSH-major] Granuloma, Plasma Cell / pathology. Ileal Diseases / pathology. Intestinal Obstruction / pathology

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19260252.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


6. Falguières T, Maak M, von Weyhern C, Sarr M, Sastre X, Poupon MF, Robine S, Johannes L, Janssen KP: Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool. Mol Cancer Ther; 2008 Aug;7(8):2498-508
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool.
  • The targeting of solid tumors requires delivery tools that resist intracellular and extracellular inactivation, and that are taken up specifically by tumor cells.
  • We have shown previously that the recombinant nontoxic B-subunit of Shiga toxin (STxB) can serve as a delivery tool to target digestive tumors in animal models.
  • Tissue samples of normal colon, benign adenomas, colorectal carcinomas, and liver metastases from 111 patients were obtained for the quantification of the expression of the cellular STxB receptor, the glycosphingolipid globotriaosyl ceramide (Gb(3) or CD77).
  • We found that compared with normal tissue, the expression of Gb(3) was strongly increased in colorectal adenocarcinomas and their metastases, but not in benign adenomas.
  • Of a given tumor sample, on average, 80% of the cells could visibly bind STxB, and upon incubation at 37 degrees C, STxB was transported to the Golgi apparatus, following the retrograde route.
  • This STxB-specific intracellular targeting allows the molecule to avoid recycling and degradation, and STxB could consequently be detected on tumor cells even 5 days after initial uptake.
  • In conclusion, the targeting properties of STxB could be diverted for the delivery of contrast agents to human colorectal tumors and their metastases, whose early detection and specific targeting remains one of the principal challenges in oncology.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / biosynthesis. Colorectal Neoplasms / therapy. Intestines / microbiology. Shiga Toxins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromatography, Thin Layer. Female. Humans. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Male. Middle Aged. Trihexosylceramides / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18687997.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Gb3 antigen; 0 / Shiga Toxins; 0 / Trihexosylceramides; 0 / stxB toxin; 71965-57-6 / globotriaosylceramide
  •  go-up   go-down


7. Beltran MA, Cruces KS: Primary tumors of jejunum and ileum as a cause of intestinal obstruction: a case control study. Int J Surg; 2007 Jun;5(3):183-91
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary tumors of jejunum and ileum as a cause of intestinal obstruction: a case control study.
  • BACKGROUND: Small-bowel tumors are rare and account for 1-2% of all gastrointestinal neoplasms.
  • Most of these tumors are found at surgery indicated for other diagnosis or intestinal obstruction.
  • The rarity, unclear presentation and diagnostic difficulty of these tumors stimulated our interest to review our experience with emergency surgery for intestinal obstruction secondary to jejunoileal tumors.
  • METHODS: We reviewed 17 patients operated on for intestinal obstruction secondary to benign and malignant primary tumors of jejunum and ileum at our institution the last 10 years.
  • The most frequent tumors found were GIST (36%) followed by lymphomas (24%) and adenocarcinomas (18%).
  • Most tumors (65%) were located in the ileum.
  • Mean survival for patients with malignant tumors was 19.5+/-13 months, and for patients with benign tumors 72+/-20 months (p<0.05).
  • CONCLUSION: Jejunoileal tumors present frequently in patients younger than 49 years of age.
  • Ileal tumors are more likely to develop intestinal obstruction than jejunal tumors.
  • [MeSH-major] Ileal Neoplasms / complications. Intestinal Obstruction / etiology. Jejunal Neoplasms / complications
  • [MeSH-minor] Abdomen, Acute / etiology. Adenocarcinoma / complications. Adult. Aged. Case-Control Studies. Female. Gastrointestinal Stromal Tumors / complications. Gastrointestinal Stromal Tumors / pathology. Humans. Leiomyoma / complications. Logistic Models. Lymphoma / complications. Lymphoma / pathology. Male. Middle Aged. Neoplasm Staging. Sarcoma / complications

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509501.001).
  • [ISSN] 1743-9159
  • [Journal-full-title] International journal of surgery (London, England)
  • [ISO-abbreviation] Int J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Petrova TV, Nykänen A, Norrmén C, Ivanov KI, Andersson LC, Haglund C, Puolakkainen P, Wempe F, von Melchner H, Gradwohl G, Vanharanta S, Aaltonen LA, Saharinen J, Gentile M, Clarke A, Taipale J, Oliver G, Alitalo K: Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype. Cancer Cell; 2008 May;13(5):407-19
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype.
  • The Drosophila transcription factor Prospero functions as a tumor suppressor, and it has been suggested that the human counterpart of Prospero, PROX1, acts similarly in human cancers.
  • PROX1 expression marks the transition from benign colon adenoma to carcinoma in situ, and its loss inhibits growth of human colorectal tumor xenografts and intestinal adenomas in Apc(min/+) mice, while its transgenic overexpression promotes colorectal tumorigenesis.
  • Furthermore, in intestinal tumors PROX1 is a direct and dose-dependent target of the beta-catenin/TCF signaling pathway, responsible for the neoplastic transformation.
  • Our data underscore the complexity of cancer pathogenesis and implicate PROX1 in malignant tumor progression through the regulation of cell polarity and adhesion.
  • [MeSH-major] Adenoma / genetics. Colonic Neoplasms / genetics. Homeodomain Proteins / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Carcinoma in Situ / genetics. Cell Line, Tumor. Colorectal Neoplasms / genetics. Disease Progression. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Phenotype. beta Catenin / physiology

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18455124.001).
  • [ISSN] 1878-3686
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0301154
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Tumor Suppressor Proteins; 0 / beta Catenin; 0 / prospero-related homeobox 1 protein
  •  go-up   go-down


9. Lewin MR, Dilworth HP, Abu Alfa AK, Epstein JI, Montgomery E: Mucosal benign epithelioid nerve sheath tumors. Am J Surg Pathol; 2005 Oct;29(10):1310-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosal benign epithelioid nerve sheath tumors.
  • Mucosal nerve sheath tumors have been well described in the gastrointestinal tract and other mucosal sites.
  • In a series of mucosal biopsies, we have encountered a distinct subset of mucosal peripheral nerve sheath tumors characterized by small epithelioid cells and a benign clinical course.
  • Such epithelioid nerve sheath tumors have been observed as a component of a larger study of colorectal "schwannomas," but herein we describe them in detail.
  • A series of 7 of these lesions detected on mucosal biopsies (6 colonic, 1 bladder) was received by a single large institution in consultation material.
  • All of the colonic lesions were discovered as small (0.2-1.0 cm) polyps during the time of colonoscopy (3 at the time of routine screening, 2 for the workup of occult blood in the stool).
  • Mucosal epithelioid nerve sheath tumors are a rare entity characterized by prominent epithelioid round to oval cells with an infiltrative growth pattern.
  • These lesions are often discovered incidentally and have a benign clinical course.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Intestinal Mucosa / pathology. Nerve Sheath Neoplasms / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160473.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Chiesa AG, Deavers MT, Veras E, Silva EG, Gershenson D, Malpica A: Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change? Int J Gynecol Pathol; 2010 Mar;29(2):108-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change?
  • At a National Cancer Institute-sponsored workshop it was proposed that the borderline category of ovarian intestinal-type mucinous tumors (OInMTs) could be eliminated if the apparent benign behavior of these tumors could be confirmed.
  • Optimal sampling and adequate sampling were defined as at least 1 section per centimeter of maximum tumor dimension and at least 1 section per 2 cm of maximum tumor dimension, respectively.
  • Tumor size ranged from 8 to 39 cm (mean 20 cm).
  • The sampling of the ovarian tumor was optimal in 28 cases and adequate in 5 cases.
  • The tumor was incompletely removed and recurred in the pelvis 1 year later.
  • Ten months later, the tumor re-recurred in the pelvis and could only be drained because of the patient's advanced age and her poor medical status.
  • The second patient with recurrent tumor had undergone a cystectomy and full staging for a borderline OInMT.
  • However, borderline OInMTs are usually large and heterogeneous, and the standard sampling protocol for them is not evidence based.
  • [MeSH-major] Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / classification. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Histocytochemistry. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Retrospective Studies. Terminology as Topic. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Gynecol Pathol. 2010 Nov;29(6):552-3; author reply 553-4 [20881857.001]
  • (PMID = 20173495.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Uenoyama Y, Seno H, Fukuda A, Sekikawa A, Nanakin A, Sawabu T, Kawada M, Kanda N, Suzuki K, Yada N, Fukui H, Chiba T: Hypoxia induced by benign intestinal epithelial cells is associated with cyclooxygenase-2 expression in stromal cells through AP-1-dependent pathway. Oncogene; 2006 Jun 1;25(23):3277-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia induced by benign intestinal epithelial cells is associated with cyclooxygenase-2 expression in stromal cells through AP-1-dependent pathway.
  • Cyclooxygenase-2 (COX-2) plays important roles in tumor development.
  • Especially in the early-stage colorectal tumors, COX-2 expression is often observed in the tumor stroma.
  • In the present study, we simulated the indirect interaction between epithelial cells and stromal cells in the process of colorectal tumor development using an in vitro co-culture model in which NIH3T3 fibroblasts were co-cultured with 'sparsely' or 'densely' populated intestinal epithelial cells, Intestine-407 as a model of premalignant or benign intestinal epithelial cells, and DLD-1 and Caco-2 as models of malignant epithelial cells.
  • Interestingly, there was pericellular hypoxia in the vicinity of NIH3T3 fibroblasts when co-cultured with 'dense' epithelial cells, and the recovery of the partial pressure of oxygen level resulted in the reduction of enhanced COX-2 expression only in NIH3T3 fibroblasts co-cultured with 'dense' Intestine-407 cells.
  • Thus, pericellular hypoxia of the stromal cells caused by densely populated epithelial cells may be one of the potent COX-2 enhancers before completion of malignant transformation during intestinal tumor development.
  • [MeSH-major] Anoxia / enzymology. Cyclooxygenase 2 / biosynthesis. Intestinal Mucosa / cytology. Intestinal Mucosa / enzymology. Membrane Proteins / biosynthesis. Signal Transduction / physiology. Transcription Factor AP-1 / physiology
  • [MeSH-minor] Animals. Caco-2 Cells. Cell Count. Cell Line, Tumor. Coculture Techniques. Enzyme Induction / physiology. Humans. Mice. NIH 3T3 Cells. Precancerous Conditions / enzymology. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Stromal Cells / enzymology. Stromal Cells / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16407821.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Transcription Factor AP-1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


12. Serra S, Asa SL, Bamberger AM, Wagener C, Chetty R: CEACAM1 expression in pancreatic endocrine tumors. Appl Immunohistochem Mol Morphol; 2009 Jul;17(4):286-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CEACAM1 expression in pancreatic endocrine tumors.
  • The aim of this study was to examine the expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in pancreatic endocrine tumors (PETs) and to correlate it with clinicopathologic parameters.
  • Sixty-nine PETs were examined for tumor size, necrosis, local peripancreatic invasion and lymphovascular invasion, lymph node, and liver metastasis.
  • The mitotic count, expressed per 10 high-power fields (HPF) and MIB1 index were assessed and tumors were classified according to the World Health Organization classification.
  • Twenty-nine tumors were from males and 40 from females, age range: 23 to 80 years (mean 52.4 y), tumor size ranged from 0.8 to 11 cm (mean 3.5 cm), 8 patients had multiple endocrine neoplasia 1 syndrome, and 1 had von Hippel-Lindau disease.
  • Twenty tumors demonstrated local invasion, 32 had lymphovascular invasion, 16 had lymph node metastasis, and 10 had liver metastasis.
  • In addition, 80% of tumors >or=2 cm in diameter were CEACAM positive (P<0.05).
  • CEACAM1-positive tumors were more frequently insulin negative (9 of 10 cases) (P=0.005) and vasoactive intestinal peptide-positive PETs were all CEACAM1 immunopositive (7 of 7 cases) (P=0.005).
  • Benign tumors and PETs of uncertain malignant behavior were more frequently CEACAM1-negative and low-grade malignant cases were CEACAM1 positive (27 of 29 cases) (P=0.001).
  • In addition, CEACAM1-positive tumors were statistically correlated with cytokeratin 19-positive tumors (P<0.05).

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19349857.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD66 antigens; 0 / Cell Adhesion Molecules; 0 / Neoplasm Proteins
  •  go-up   go-down


13. Ferreira CR, Carvalho JP, Soares FA, Siqueira SA, Carvalho FM: Mucinous ovarian tumors associated with pseudomyxoma peritonei of adenomucinosis type: immunohistochemical evidence that they are secondary tumors. Int J Gynecol Cancer; 2008 Jan-Feb;18(1):59-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous ovarian tumors associated with pseudomyxoma peritonei of adenomucinosis type: immunohistochemical evidence that they are secondary tumors.
  • Pseudomyxoma peritonei (PMP) is a clinical condition initially thought to be related to ovarian mucinous tumors; however, immunohistochemistry and molecular biology techniques have convincingly made the link to appendiceal mucinous neoplasms, resulting in changes in histologic and clinical approaches.
  • The objective of this study was to compare the immunohistochemical profile of ovarian tumors associated with PMP and intestinal mucinous ovarian neoplasms without PMP.
  • The study was retrospective and included 28 intestinal ovarian mucinous tumors selected from the files of the Division of Surgical Pathology of the University of Sao Paulo Medical School, from 1996 to 2005.
  • Comparisons of borderline histology with that of benign/malignant tumors also revealed differences in MUC2 and CK20.
  • Our results confirm that there is a distinct profile of intestinal ovarian tumors associated with pseudomyxoma, particularly with respect to the expression of the gel-forming mucin MUC2.
  • The profile of borderline tumors, even in cases without PMP, was distinct from that of other primary mucinous tumors of the intestinal type, suggesting that borderline histology may represent a secondary tumor or a less aggressive variant of PMP.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Biomarkers, Tumor / metabolism. Intestinal Neoplasms / pathology. Neoplasms, Second Primary / pathology. Ovarian Neoplasms / pathology. Pseudomyxoma Peritonei / pathology

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17511804.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-20; 0 / Mucins
  •  go-up   go-down


14. Chiu YC, Lin JW, Changchien CS, Huang CC, Liu SY, Yi LN, Chiu KW, Wu KL, Chen YY, Chou FF, Hu TH: Clinicopathological characteristics and prognosis of patients with small intestinal stromal tumors. J Formos Med Assoc; 2005 Dec;104(12):905-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics and prognosis of patients with small intestinal stromal tumors.
  • BACKGROUND AND PURPOSE: Gastrointestinal stromal tumors (GISTs) involving the small intestine are less common than those involving the stomach, and data on small intestinal stromal tumors (SISTs) are more limited.
  • This study investigated the clinicopathological characteristics and prognostic factors of SISTs and compared them with those of gastric stromal tumors (GSTs).
  • METHODS: A total of 82 surgically resected and pathologically diagnosed smooth muscle tumors of small bowel in patients treated from January 1986 to December 2000 were included.
  • Immunohistochemical studies were performed on these tumors with antibodies of CD117, CD34, smooth muscle actin (SMA), desmin and S-100.
  • RESULTS: Among the 82 small intestine tumors, 71 were CD117-positive (86.6%) and were classified as SISTs.
  • Survival analysis demonstrated that tumor size < 5 cm (p = 0.021), mitosis number < 5/50 high-power field (p < 0.001), SMA-positive (p = 0.027), non-epithelioid cell type (p = 0.005) and tumor with skeinoid fibers (p = 0.010) predicted longer disease-free survival after operation.
  • Multivariate analysis revealed that mitotic number (p = 0.001), cell morphology (p = 0.031) and tumor size (p = 0.004) were independent prognostic factors.
  • SMA reactivity is a predictor of benign clinical behavior in SISTs.
  • Tumor mitotic numbers, tumor size, and cell type were independent prognostic factors for patients with SISTs after operation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607447.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


15. Fukumoto A, Tanaka S, Shishido T, Oka S, Chayama K: [Diagnosis and treatment for benign small bowel tumor]. Nihon Rinsho; 2008 Jul;66(7):1305-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment for benign small bowel tumor].
  • Even if small bowel tumors are benign, they need to be treated when they cause symptoms, such as gastrointestinal bleeding or enteric intussusception.
  • It became possible to perform endoscopic treatment for small bowel lesions using DBE.
  • Therefore for preventing surgical operation, it became important to detect small bowel tumors while endoscopic treatment is possible.
  • CE has potential to survey small bowel tumors, especially in patients with polyposis.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestine, Small

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18616121.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 20
  •  go-up   go-down


16. de Vries JJ, Vogten JM, de Bruin PC, Boerma D, van de Pavoordt HD, Hagendoorn J: Mesenterical lymphangiomatosis causing volvulus and intestinal obstruction. Lymphat Res Biol; 2007;5(4):269-73
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesenterical lymphangiomatosis causing volvulus and intestinal obstruction.
  • Lymphangiomas are benign tumors consisting of lymphatic vasculature that generally occur in the skin and soft tissues.
  • Rarely, lymphangiomas occur in the gastrointestinal tract.
  • Here, we report a case of a 13-year-old girl presenting with an intestinal obstruction.
  • [MeSH-major] Intestinal Neoplasms / pathology. Intestinal Obstruction / etiology. Intestinal Volvulus / etiology. Lymphangioma / pathology. Mesentery / pathology

  • Genetic Alliance. consumer health - Lymphangiomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18370918.001).
  • [ISSN] 1539-6851
  • [Journal-full-title] Lymphatic research and biology
  • [ISO-abbreviation] Lymphat Res Biol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Kapran Y, Bauersfeld J, Anlauf M, Sipos B, Klöppel G: Multihormonality and entrapment of islets in pancreatic endocrine tumors. Virchows Arch; 2006 Apr;448(4):394-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multihormonality and entrapment of islets in pancreatic endocrine tumors.
  • We analyzed pancreatic endocrine tumors (PETs) from 200 patients for the incidence of multihormonality and entrapped islets and correlated the results with clinicopathological features.
  • Classified according to the WHO classification, there were 32 well-differentiated benign PETs, 85 well-differentiated PETs with uncertain behavior, and 83 well-differentiated malignant PETs.
  • All tumors were immunostained for pancreatic hormones (insulin, glucagon, somatostatin, and pancreatic polypeptide) and for additional hormones such as gastrin, vasoactive intestinal polypeptide, calcitonin, seratonin, and adrenocorticotropic hormone.
  • Multihormonality was found in 34% of all PETs and it was a frequent finding in the tumors of the uncertain behavior (38.8%) group.
  • Islet entrapment was found in 57 tumors (28.5%) and was significantly more frequent in PETs with uncertain and malignant behavior than benign ones (p=0.01).
  • Of these 57 tumors, 45 (79%) tumors had accompanying ductule entrapment.
  • Ductule entrapment did not show significant correlation with malignancy and was a more frequent finding in nonfunctioning tumors.
  • We conclude that the incidence of multihormonality in PETs is not as high as suggested previously and islet entrapping may reflect aggressive tumor growth and may be a complementary criterion for predicting the biological behavior of PETs.
  • [MeSH-major] Adenoma, Islet Cell / pathology. Carcinoma, Islet Cell / pathology. Islets of Langerhans / pathology. Pancreatic Hormones / metabolism. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Count. Child. Child, Preschool. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16418841.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Pancreatic Hormones
  •  go-up   go-down


18. Kume K, Murata I, Yoshikawa I, Yamasaki M, Kanda K, Otsuki M: Endoscopic piecemeal mucosal resection of large colorectal tumors. Hepatogastroenterology; 2005 Mar-Apr;52(62):429-32
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic piecemeal mucosal resection of large colorectal tumors.
  • BACKGROUND/AIMS: Since endoscopic en bloc resection of large and sessile tumors is technically difficult, endoscopic en bloc piecemeal mucosal resection (EPMR) is usually chosen for resection of such tumors.
  • Tumors resected by EPMR are, however, difficult to evaluate histologically.
  • METHODOLOGY: We removed 30 large colorectal tumors in 30 patients by EPMR between 1992-2000.
  • Patients in whom no residual tumor was found by both endoscopic and histologic examination were considered to be "cured".
  • RESULTS: Histological examination of the resected tumor tissues revealed malignancy in 43.3% (13/30).
  • Three patients had invasive malignant tumors and underwent surgery.
  • Following complete endoscopic resection, recurrences were observed in 2 patients with benign tumors, which were resected by additional endoscopic resection.
  • All patients including the two with non-invasive malignant tumors remain free from recurrence during a mean follow-up period of 45.2 months (range, 3-104 months).
  • CONCLUSIONS: EPMR of benign or non-invasive large malignant tumors is a safe and effective procedure.
  • Complete excision of large, sessile and non-invasive tumors is possible, although complete removal by EPMR cannot be verified histologically.
  • [MeSH-major] Adenoma / surgery. Carcinoma / surgery. Colorectal Neoplasms / surgery. Endoscopy, Digestive System / methods. Intestinal Mucosa / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colonoscopy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816450.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


19. Schwartz GD, Barkin JS: Small-bowel tumors detected by wireless capsule endoscopy. Dig Dis Sci; 2007 Apr;52(4):1026-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small-bowel tumors detected by wireless capsule endoscopy.
  • Small bowel tumors are difficult to diagnose because of their endoscopic inaccessibility.
  • The purpose of this report is to describe the largest series of patients with small bowel tumors detected by capsule endoscopy.
  • Eighty six patients were derived from the Given Imaging clinical database on a survey of Pillcam SB capsule users who were diagnosed with 87 small bowel tumors, 1 cecal tumor, and 1 gastric tumor.
  • All patients have histologically confirmed tumors.
  • Malignant tumors comprised 61% (54/89) and benign 39% (35/89).
  • Of the 87 reported small bowel tumors, 4 were identified in the duodenum, 43 tumors were identified in the jejunum, 18 tumors were identified in the ileum, and 22 tumors were located in the mid to distal small bowel.
  • The most common malignant tumors were adenocarcinoma, carcinoids, melanomas, lymphomas, and sarcomas.
  • The most common benign tumors were GIST, hemangiomas, hamartomas, adenomas, and granulation tissue polyps.
  • Capsule endoscopy is the diagnostic procedure of choice in patients with suspected small bowel tumors.
  • [MeSH-major] Capsule Endoscopy. Endoscopy, Gastrointestinal. Intestinal Neoplasms / diagnosis. Intestine, Small

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17380403.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Daum O, Hatlova J, Mandys V, Grossmann P, Mukensnabl P, Benes Z, Michal M: Comparison of morphological, immunohistochemical, and molecular genetic features of inflammatory fibroid polyps (Vanek's tumors). Virchows Arch; 2010 May;456(5):491-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of morphological, immunohistochemical, and molecular genetic features of inflammatory fibroid polyps (Vanek's tumors).
  • Vanek's tumor (inflammatory fibroid polyp) is a rare benign lesion occurring throughout the digestive tract.
  • Classical Vanek's tumor contains concentric formations of proliferating spindle cells which are CD34 positive.
  • Atypical, inflammatory pseudotumor-like Vanek's tumor lacks concentric formations and is CD34 negative.
  • Recently, mutations in platelet-derived growth factor receptor alpha (PDGFRA) were reported in gastric and small intestinal Vanek's tumors.
  • In this study, KIT exons 9, 11, 13, and 17, PDGFRA exons 12, 14, and 18, and a part of exon 15 BRAF for point mutation V600E were screened in 23 cases of Vanek's tumor, both classical (n = 16) and inflammatory pseudotumor-like (n = 7).
  • Six Vanek's tumors harbored activating mutations in PDGFRA exons 12 (n = 5) and 18 (n = 1) respectively: S566_E571delinsK (n = 1), S566_E571delinsR (n = 4), and D842 del (n = 1).
  • The mutations were detected in the classical (n = 5), as well as inflammatory pseudotumor-like (n = 1) Vanek's tumors.
  • The results of this study suggest that the two morphological patterns of Vanek's tumor more probably represent only variants of one type of tumor than two different lesions.
  • Furthermore, BRAF mutations were not shown to drive growth of PDGFRA wild-type Vanek's tumors.
  • [MeSH-major] Intestinal Diseases / pathology. Leiomyoma / genetics. Leiomyoma / pathology. Polyps / genetics. Polyps / pathology. Receptor, Platelet-Derived Growth Factor alpha / genetics. Stomach Diseases / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Exons. Female. Gastrointestinal Tract / pathology. Humans. Male. Middle Aged. Mutation. Proto-Oncogene Proteins B-raf / genetics

  • MedlinePlus Health Information. consumer health - Stomach Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20393746.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


21. Skrzypczak M, Goryca K, Rubel T, Paziewska A, Mikula M, Jarosz D, Pachlewski J, Oledzki J, Ostrowski J: Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLoS One; 2010;5(10)
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability.
  • Based on a consensus of the results obtained by two normalization algorithms, and two probe set sorting criteria, we identified 14 and 17 KEGG signaling and metabolic pathways that are significantly altered between normal and tumor samples and between benign and malignant tumors, respectively.
  • [MeSH-major] Adenocarcinoma / metabolism. Colonic Neoplasms / metabolism. Oligonucleotide Array Sequence Analysis. Oncogenes. Signal Transduction
  • [MeSH-minor] Algorithms. Humans. Intestinal Mucosa / metabolism. Reproducibility of Results

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3124-30 [11306497.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3544-9 [11325815.001]
  • [Cites] Bioinformatics. 2001 Jun;17(6):509-19 [11395427.001]
  • [Cites] Neoplasia. 2001 Sep-Oct;3(5):395-401 [11687950.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4352-63 [12154040.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Gut. 2003 Aug;52(8):1148-53 [12865273.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Bioinformatics. 2004 Feb 12;20(3):323-31 [14960458.001]
  • [Cites] Oncogene. 2004 Feb 19;23(7):1377-91 [14973550.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Eur J Cancer. 1999 Mar;35(3):335-51 [10448282.001]
  • [Cites] Gastroenterology. 2005 Feb;128(2):480-6 [15685558.001]
  • [Cites] Genome Biol. 2005;6(2):R16 [15693945.001]
  • [Cites] Oncol Rep. 2005 Mar;13(3):517-24 [15706427.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1587-97 [15735049.001]
  • [Cites] BMC Bioinformatics. 2005;6:80 [15799785.001]
  • [Cites] Int J Colorectal Dis. 2005 Sep;20(5):391-402 [15883783.001]
  • [Cites] Expert Rev Mol Diagn. 2006 May;6(3):465-80 [16706747.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1829-36 [16721809.001]
  • [Cites] J Mol Med (Berl). 2006 Oct;84(10):872-82 [16924468.001]
  • [Cites] World J Gastroenterol. 2006 Nov 21;12(43):6998-7006 [17109495.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1775(1):103-37 [17010523.001]
  • [Cites] Nature. 2007 Mar 8;446(7132):153-8 [17344846.001]
  • [Cites] J Mol Med (Berl). 2007 Jul;85(7):733-43 [17415542.001]
  • [Cites] Cancer Detect Prev. 2007;31(4):282-95 [17936523.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Mol Cancer Res. 2007 Dec;5(12):1263-75 [18171984.001]
  • [Cites] Mol Cancer. 2007;6:79 [18081933.001]
  • [Cites] BMC Bioinformatics. 2008;9:140 [18318917.001]
  • [Cites] BMC Bioinformatics. 2008;9:164 [18366762.001]
  • [Cites] Surg Clin North Am. 2008 Aug;88(4):681-704, v [18672136.001]
  • [Cites] Dis Markers. 2008;25(1):1-16 [18776587.001]
  • [Cites] Nat Biotechnol. 2008 Sep;26(9):1003-10 [18711341.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2835-45 [18843029.001]
  • [Cites] World J Gastroenterol. 2008 Oct 14;14(38):5887-92 [18855989.001]
  • [Cites] Biotechniques. 2008 Nov;45(5):501-20 [19007336.001]
  • [Cites] Cell Oncol. 2009;31(1):19-29 [19096147.001]
  • [Cites] Cancer Treat Rev. 2009 May;35(3):201-9 [19081199.001]
  • [Cites] Gastroenterology. 2009 Jul;137(1):165-75 [19328798.001]
  • [Cites] J Biomed Inform. 2009 Aug;42(4):605-11 [19535009.001]
  • [Cites] Expert Rev Mol Diagn. 2009 Sep;9(6):623-30 [19732006.001]
  • [Cites] Br J Cancer. 2010 Feb 16;102(4):765-73 [20087348.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):41-56 [17210682.001]
  • [ErratumIn] PLoS One. 2010;5(12) doi: 10.1371/annotation/8c585739-a354-4fc9-a7d0-d5ae26fa06ca. Ostrowsk, Jerzy [corrected to Ostrowski, Jerzy]
  • (PMID = 20957034.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2948500
  •  go-up   go-down


22. Lasota J, vel Dobosz AJ, Wasag B, Wozniak A, Kraszewska E, Michej W, Ptaszynski K, Rutkowski P, Sarlomo-Rikala M, Steigen SE, Schneider-Stock R, Stachura J, Chosia M, Ogun G, Ruka W, Siedlecki JA, Miettinen M: Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors. Lab Invest; 2007 Oct;87(10):1029-41
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors.
  • Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of gastrointestinal tract.
  • GISTs range from benign indolent neoplasms to highly malignant sarcomas.
  • In this study, we report 36 GIST patients whose tumors had homozygous KIT exon 11 mutations detected by direct sequencing of PCR products.
  • Loss of heterozygosity in KIT locus and other chromosome 4 loci were documented in majority of these tumors.
  • Homozygous KIT exon 11 mutations were found in 33 primary tumors and 7 metastatic lesions.
  • In two cases, shift from heterozygosity to homozygosity was documented during tumor progression being present in metastases, but not in primary tumors.
  • Among primary GISTs, there were 16 gastric, 18 intestinal and 2 from unknown locations.
  • An average primary tumor size was 12 cm and average mitotic activity 32/50 HPFs.
  • Out of 32 tumors 29 (90.6%) with complete clinicopathologic data were diagnosed as sarcomas with more than 50% risk of metastatic disease, and 26 of 29 patients with follow-up had metastases or died of disease.
  • [MeSH-major] Gastrointestinal Stromal Tumors / genetics. Loss of Heterozygosity. Neoplasm Metastasis / genetics. Proto-Oncogene Proteins c-kit / genetics

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lab Invest. 2008 May;88(5):456-7 [18432212.001]
  • (PMID = 17632543.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


23. Gao Y, Zhang B: [Expression of TEIF protein in colorectal tumors and its correlation with centrosome abnormality]. Ai Zheng; 2009 Dec;28(12):1277-82
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of TEIF protein in colorectal tumors and its correlation with centrosome abnormality].
  • BACKGROUND AND OBJECTIVE: Telomerase transcriptional elements-interacting factor (TEIF) gene found recently by our research group is a transcription factor of a kind of human telomerase reverse transcriptase (hTERT) gene, and expresses in many kinds of tumor tissues.
  • This study was to evaluate the expression of TEIF protein in human colorectal tumors and to explore its correlation with centrosome abnormality.
  • METHODS: The expression of TEIF in 10 specimens of normal intestinal mucosa tissue, 30 specimens of colorectal cancer, and 54 specimens of colorectal adenoma was detected by immunohistochemistry.
  • RESULTS: Immunohistochemistry results showed that the differences of TEIF protein expression between the normal group and each tumor groups were statistically significant (P<0.01), and the difference of TEIF protein expression between the malignant tumor group and the benign group was not significant (P>0.05).
  • CONCLUSIONS: TEIF protein and centrosome amplification is commonly found in colorectal tumors.
  • The expression level of TEIF is related to tumor histological grade and malignant degree.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Centrosome / pathology. Colorectal Neoplasms / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Intestinal Mucosa / metabolism. Male. Middle Aged. Tubulin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19958622.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Transcription Factors; 0 / Tubulin; EC 2.7.1.- / SCYL1 protein, human
  •  go-up   go-down


24. Suárez Moreno RM, Hernández Ramírez DA, Madrazo Navarro M, Salazar Lozano CR, Martínez Gen R: Multiple intestinal lipomatosis. Case report. Cir Cir; 2010 Mar-Apr;78(2):163-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple intestinal lipomatosis. Case report.
  • BACKGROUND: Intestinal lipomatosis is a rare disease with an incidence at autopsy ranging from 0.04 to 4.5%.
  • Intestinal barium studies, ultrasonography and computed tomography (CT) are useful diagnostic techniques.
  • Abdominal CT with contrast enhancement demonstrated multiple submucosal masses in stomach and small bowel.
  • No specific treatment, invasive procedures or surgery were performed for the asymptomatic intestinal lipomas.
  • CONCLUSIONS: Benign tumors of the small bowel are relatively rare, with lipoma being the most common type.
  • [MeSH-major] Intestinal Diseases / diagnosis. Intestine, Small. Lipomatosis / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20478119.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


25. Lasota J, Wang ZF, Sobin LH, Miettinen M: Gain-of-function PDGFRA mutations, earlier reported in gastrointestinal stromal tumors, are common in small intestinal inflammatory fibroid polyps. A study of 60 cases. Mod Pathol; 2009 Aug;22(8):1049-56
Genetics Home Reference. consumer health - PDGFRA gene.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gain-of-function PDGFRA mutations, earlier reported in gastrointestinal stromal tumors, are common in small intestinal inflammatory fibroid polyps. A study of 60 cases.
  • The inflammatory fibroid polyp is a rare benign lesion occurring throughout the digestive tract.
  • In this study, PDGFRA exons 12, 14, and 18 were screened for activating mutations in 60 small intestinal inflammatory fibroid polyps.
  • However, 1835_1852delinsCGC leading to the same S566_E571delinsR, were found in two tumors.
  • Similar gain-of-function PDGFRA mutations reported in gastrointestinal stromal tumors have been considered to be a driving pathogenetic force.
  • This study showed consistent expression and common mutational activation of PDGFRA in small intestinal inflammatory fibroid polyps as in their gastric counterparts, and these lesions should be considered PDGFRA-driven benign neoplasms.
  • [MeSH-major] Biomarkers, Tumor / genetics. Intestinal Neoplasms / genetics. Intestinal Polyps / genetics. Leiomyoma / genetics. Receptor, Platelet-Derived Growth Factor alpha / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. DNA Mutational Analysis. Female. Gastrointestinal Stromal Tumors / genetics. Humans. Immunohistochemistry. Intestine, Small / pathology. Male. Middle Aged. Mutation. Polymerase Chain Reaction. Young Adult

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19448595.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


26. Lázár G, Paszt A, Simonka Z, Rokszin R, Abrahám S: [Laparoscopic surgery in colorectal tumors]. Magy Onkol; 2010 Jun;54(2):117-22
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic surgery in colorectal tumors].
  • The minimally invasive technique, by means of the undoubted advantages of the method, has become fully accepted in the surgical treatments of the most benign and functional diseases.
  • Today it has been proven that the laparoscopic technique is safely usable also in the surgical treatment of colorectal tumors.
  • The authors, analyzing their own and the international experiences, present the laparoscopic surgical treatment of colorectal tumors.
  • Seventy-four patients were treated with laparoscopic-assisted colorectal intestinal resection in the Department of Surgery of the University of Szeged between January 1, 2005 and December 31, 2008.
  • The histological processes of specimens justified tumor-free oral, aboral and circumferential resection in all cases.
  • Summarizing our own and international experiences it can be stated that the laparoscopic surgeries performed due to colorectal tumors are safe, and are also appropriate with respect to oncosurgery.
  • [MeSH-major] Colorectal Neoplasms / surgery. Digestive System Surgical Procedures / methods. Laparoscopy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colectomy / methods. Female. Humans. Hungary. Male. Middle Aged. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20576587.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


27. Farnedi A, Eusebi LH, Poli F, Foschini MP: Immunohistochemical expression of the human sodium/iodide symporter distinguishes malignant from benign gastric lesions. Int J Surg Pathol; 2009 Aug;17(4):327-34
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of the human sodium/iodide symporter distinguishes malignant from benign gastric lesions.
  • MATERIALS AND METHODS: Seventy-seven samples were stained immunohistochemically with a monoclonal antibody for hNIS, including 14 with normal gastric mucosa, 14 with chronic atrophic gastritis with foveolar hyperplasia, 15 with chronic atrophic gastritis with intestinal metaplasia, 6 with chronic atrophic gastritis with atypical regenerative hyperplasia, 8 with chronic atrophic gastritis with dysplasia, 15 with invasive adenocarcinoma, 3 with well-differentiated neuroendocrine tumor, and 2 with gastrointestinal stromal tumors (GISTs).
  • RESULTS: hNIS stained the basolateral cytoplasmic portion of foveolae in normal mucosa, in 13 cases of chronic atrophic gastritis with foveolar hyperplasia, and in only 1 case of regenerative atypical hyperplasia. hNIS was consistently absent in intestinal metaplasia, in dysplastic glands, and in the cells constituting invasive carcinoma, well-differentiated neuroendocrine tumors, and GIST.
  • [MeSH-major] Gastritis, Atrophic / diagnosis. Gastrointestinal Stromal Tumors / diagnosis. Neuroendocrine Tumors / diagnosis. Precancerous Conditions / pathology. Stomach Neoplasms / diagnosis. Symporters / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19124451.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Symporters; 0 / sodium-iodide symporter
  •  go-up   go-down


28. de Herder WW, Kwekkeboom DJ, Valkema R, Feelders RA, van Aken MO, Lamberts SW, van der Lely AJ, Krenning EP: Neuroendocrine tumors and somatostatin: imaging techniques. J Endocrinol Invest; 2005;28(11 Suppl International):132-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine tumors and somatostatin: imaging techniques.
  • Tumors and metastases bearing the somatostatin receptor subtypes 2 (SSTR2) or SSTR5 can be visualized in vivo after injection of radiolabeled octapeptide somatostatin analogs like 111In-pentetreotide.
  • The sensitivity of 111In-pentetreotide scintigraphy for the detection of carcinoid tumors is 86-95%.
  • The sensitivity of 111In-pentetreotide scintigraphy for the detection of gastrinomas, vasoactive intestinal polypeptide-secreting tumors, and glucagonomas as well as clinically non-functioning lesions is 75-100%.
  • 111In-pentetreotide scintigraphy generally has a lower detection rate for benign pheochromocytomas than 123I-MIBG scintigraphy, but it can have a complementary role for the staging of malignant pheochromocytomas.
  • 111In-pentetreotide scintigraphy has been successful for the localization of extra-pituitary ACTH-secreting tumors and their metastases, and especially for occult tumors.
  • A large variety of lesions in and around the pituitary region express somatostatin receptors and, therefore, can be visualized by 111In-pentetreotide scintigraphy.
  • [MeSH-major] Neuroendocrine Tumors / radionuclide imaging. Somatostatin
  • [MeSH-minor] Carcinoid Tumor / radionuclide imaging. Gastrointestinal Neoplasms / radionuclide imaging. Humans. Indium Radioisotopes. Paraganglioma / radionuclide imaging. Pheochromocytoma / radionuclide imaging. Pituitary Neoplasms / radionuclide imaging. Receptors, Somatostatin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625862.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Indium Radioisotopes; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 0 / somatostatin receptor 5; 51110-01-1 / Somatostatin; G083B71P98 / pentetreotide
  • [Number-of-references] 49
  •  go-up   go-down


29. Yang WL, Zhang XC, Yan ZQ, Zhang HM, Zhao Z, Zhang JG, Wang YJ: [Clinical analysis of primary small intestinal neoplasms in 305 cases]. Zhonghua Zhong Liu Za Zhi; 2007 Oct;29(10):781-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of primary small intestinal neoplasms in 305 cases].
  • OBJECTIVE: To summarive the experience in diagnosis and treatment of primary small intestinal neoplasm.
  • METHODS: The data of 305 patients with pathologically confirmed primary small intestinal tumor collected from 6 hospitals around the Songhua River during the past 33 years were analyzed retrospectively.
  • RESULTS: There were 42 benign and 263 malignant tumors in this series with a ratio of 1: 6.26.
  • The 263 malignant tumors in this series consisted of 135 adenocarcinomas, 57 malignant stromal tumors, 37 malignant lymphomas, 20 carcinoids, and etc.
  • Chronic occult bleeding, gradual of body weight loss and mild abdominal pain (three obscurities) were the common clinical features and alerting massage of intestinal tumor.
  • Correct preoperative diagnostic rate was only 57.0% (174/305) due to difficulty in early diagnosis, which was 67.2% (92/137) in the duodenal tumors, and 51.9% (82/168) in the jejunoileal tumors.
  • All of the 42 benign tumors were resected completely.
  • For the 263 patients with malignant tumors, radical dissection was performed in 153, palliative resection in 34, and gut by-pass or biopsy in 76.
  • The median survival of the patients who underwent radical resection of their malignant tumors was 92 months, which was significantly higher than that of the other groups.
  • CONCLUSION: Early diagnosis of primary small intestinal tumors is difficult and with a preoperative misdiagnosis rate of 43.0%.
  • Total intestinal barium swallowing, endoscopy and superior mesenteric arteriography are three critical examinations for diagnosis and location.
  • The primary small intestinal tumor should be resected as early as possible if no distant metastasis is detected.
  • [MeSH-major] Adenocarcinoma. Diagnostic Errors. Digestive System Surgical Procedures / methods. Duodenal Neoplasms
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoid Tumor / diagnosis. Carcinoid Tumor / secondary. Carcinoid Tumor / surgery. Female. Gastrointestinal Stromal Tumors / diagnosis. Gastrointestinal Stromal Tumors / secondary. Gastrointestinal Stromal Tumors / surgery. Humans. Ileal Neoplasms / diagnosis. Ileal Neoplasms / pathology. Ileal Neoplasms / surgery. Jejunal Neoplasms / diagnosis. Jejunal Neoplasms / pathology. Jejunal Neoplasms / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lymphatic Metastasis. Lymphoma / diagnosis. Lymphoma / pathology. Lymphoma / surgery. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396694.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


30. Gagliano E, Tonante A, Lo Schiavo MG, Bonanno L, Taranto F, Sturniolo G: [Ileal leiomyosarcoma presenting with an episode of acute massive intestinal bleeding]. Chir Ital; 2006 Jul-Aug;58(4):519-24
Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ileal leiomyosarcoma presenting with an episode of acute massive intestinal bleeding].
  • The aim of this article was to present a case of gastrointestinal stromal tumour (GIST) presenting with acute intestinal bleeding.
  • Histological criteria are by no means of absolute value: tumours considered benign on the basis of histology may present a malignant behaviour in the course of time, with the development of metastases and recurrences.
  • In this regard, a number of predictive malignancy indices have been identified such as the patient's age, tumour size, presence of haemorrhage and necrotic areas, high mitotic index (> 5 mitoses/50 HFP), and kit-gene mutations.
  • The Authors stress the diagnostic importance of 99m Tc-RBC scintigraphy in the case reported and agree with the literature as to the appropriate therapy, consisting in intestinal resection.
  • The therapy of active GIST is essentially surgical and consists in resection of the intestinal tract affected by the tumour: lymphadenectomy must be performed only in case of need, because GIST metastasis preferably via the blood stream.
  • [MeSH-major] Gastrointestinal Hemorrhage / etiology. Ileal Neoplasms / complications. Leiomyosarcoma / complications
  • [MeSH-minor] Female. Gastrointestinal Stromal Tumors / complications. Humans. Middle Aged. Radiopharmaceuticals. Technetium. Treatment Outcome

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16999158.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 7440-26-8 / Technetium
  •  go-up   go-down


31. Shevchenko IuL, Stoĭko IuM, Levchuk AL, Stepaniuk IV, Seregin MV: [Modern capabilities of the diagnostics and surgical treatment of tumors of the small bowel]. Vestn Khir Im I I Grek; 2010;169(5):45-51
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Modern capabilities of the diagnostics and surgical treatment of tumors of the small bowel].
  • During the recent 6 years (2004-2010) tumors of the small intestine were diagnosed in 19 patients.
  • Mean age of the patients with benign tumors was 63 years, with malignant tumors--57 years (age variations from 19 to 82 years).
  • In 9 patients tumors were localized in the jejunum, in 10 patients--in the ileum.
  • In 33.3% of the patients clinical manifestations of benign tumors of the small bowel were as episodes of intestinal bleedings which were not intensive as a rule, but were of recurrent character.
  • Malignant tumors of the jejunum had clinical manifestations in 87% of patients.
  • Most frequent symptoms were spastic or diffuse pains in the abdomen (63% of the patients), loss of the body mass (50%), intestinal obstruction (27.7%), intestinal bleedings (5.5%).
  • [MeSH-major] Jejunal Neoplasms / diagnosis. Jejunal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21137260.001).
  • [ISSN] 0042-4625
  • [Journal-full-title] Vestnik khirurgii imeni I. I. Grekova
  • [ISO-abbreviation] Vestn. Khir. Im. I. I. Grek.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


32. Xia SY, Li R, Song SB, Liang FQ: [Diagnosis and surgical therapy of primary retroperitoneal neurogenic tumors]. Zhonghua Yi Xue Za Zhi; 2009 Jun 9;89(22):1567-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and surgical therapy of primary retroperitoneal neurogenic tumors].
  • OBJECTIVE: To explore the diagnosis and surgical therapy for retroperitoneal neurogenic tumors (PRNTs).
  • METHODS: The clinical records of 79 surgically treated patients with retroperitoneal neurogenic tumor were retrospectively analyzed.
  • Pathological analysis identified 19 patients with neurofibroma, 8 with neurilemmoma, 4 with paraganglioma, 21 with neurofibrosarcoma, 14 with malignant neurilemmoma, 6 with malignant paraganglioma, 5 with neuroectodermal tumor and 2 with neuroblastoma.
  • The mortality rate of PRNT operation is was 1.3%, 3-year recurrence rate of benign tumor 0%, 5-year recurrence rate of benign tumor 12.9%, reoperation rate 100%, 5-year survival rate 100%.
  • 3 years recurrence rate of malignancy tumor 41.6%, reoperation rate 90%, 5 years recurrence rate of malignancy tumor 79.1% and 5 years survival rate is 62.5%.
  • Pre-operative preparation of intestinal tract and blood, maintaining the intactness of involved nerve are important for tumor resection.
  • To prevent tumor recurrence, the key surgical techniques are to minimize tumor residues and .
  • [MeSH-major] Neuroectodermal Tumors / diagnosis. Neuroectodermal Tumors / surgery. Retroperitoneal Neoplasms / diagnosis. Retroperitoneal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19953887.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


33. Ponsaing LG, Kiss K, Hansen MB: Classification of submucosal tumors in the gastrointestinal tract. World J Gastroenterol; 2007 Jun 28;13(24):3311-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classification of submucosal tumors in the gastrointestinal tract.
  • This review is part two of three, which will present an update on the classification of gastrointestinal submucosal tumors.
  • Part one treats of the diagnosis and part three of the therapeutic methods regarding gastrointestinal submucosal tumors.
  • In the past there has been some confusion as to the classification of gastrointestinal submucosal tumors.
  • Literature searches were performed to find information related to classification of gastrointestinal submucosal tumors.
  • Based on these searches the twelve most frequent submucosal tumor types were chosen for description of their classification.
  • The factors that indicate whether tumors are benign or malignant are mainly size and number of mitotic counts.
  • Gastrointestinal stromal tumors are defined mainly by their CD117 positivity.
  • In the future, there should be no more confusion between gastrointestinal stromal tumors and other types of submucosal tumors.
  • [MeSH-major] Gastrointestinal Neoplasms / classification
  • [MeSH-minor] Antigens, CD34 / analysis. Gastric Mucosa / pathology. Gastrointestinal Stromal Tumors / classification. Gastrointestinal Stromal Tumors / pathology. Humans. Intestinal Mucosa / pathology. Proto-Oncogene Proteins c-kit / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17659669.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC4172710
  •  go-up   go-down


34. Zang L, Hu WG, Yan XW, Zhang T, Ma JJ, Ye Q, Feng B, Wang ML, Lu AG, Li JW, Zhong J, Zheng MH: Laparoscopic treatment for small intestinal bleeding: a report of 77 cases. J Laparoendosc Adv Surg Tech A; 2010 Jul-Aug;20(6):521-5
MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic treatment for small intestinal bleeding: a report of 77 cases.
  • BACKGROUND: Morbidity of small intestinal disease is rare and the associated lesion is hard to be detected due to lack of specific manifestations and effective diagnostic approaches.
  • Hematochezia and melena are the most common symptoms in small intestinal diseases.
  • Hence, small intestinal disease is an important differential diagnosis when hematochezia or melena occurs, especially when gastric and colonic diseases are excluded.
  • As the small intestinal lesion is hard to be located preoperatively, laparotomy used to be performed without a preoperative location.
  • With the development of laparoscopic technique, laparoscopic operations are more frequently applied to surgical disease, despite their benign or malignant nature.
  • Generally, almost all kinds of small intestinal disease can be treated with laparoscopic surgery.
  • METHODS: Clinical data of 77 patients with small intestinal bleeding undergoing laparoscopic or laparoscopy-assisted operations from April 2003 to December 2008 were included, and their clinical information were analyzed retrospectively.
  • There was 1 case of gastrointestinal stromal tumor with local recurrence and hepatic metastasis.
  • Four patients died from metastasis of malignant tumors during the follow-up from 2 to 70 months after operations.
  • CONCLUSIONS: Laparoscopic treatment in small intestinal bleeding is feasible, safe, and minimally invasive.
  • It may be widely used in the future for its good therapeutic outcomes and improved diagnostic chance in small intestinal bleeding diseases.
  • [MeSH-major] Gastrointestinal Hemorrhage / surgery. Intestine, Small. Laparoscopy
  • [MeSH-minor] Adolescent. Adult. Aged. Blood Loss, Surgical. Female. Humans. Intestinal Neoplasms / diagnosis. Length of Stay. Male. Melena / diagnosis. Middle Aged. Postoperative Complications. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Laparoendosc Adv Surg Tech A. 2010 Nov;20(9):771 [20874417.001]
  • (PMID = 20687815.001).
  • [ISSN] 1557-9034
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Agaimy A, Pelz AF, Wieacker P, Roessner A, Wünsch PH, Schneider-Stock R: Gastrointestinal stromal tumors of the vermiform appendix: clinicopathologic, immunohistochemical, and molecular study of 2 cases with literature review. Hum Pathol; 2008 Aug;39(8):1252-7
Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumors of the vermiform appendix: clinicopathologic, immunohistochemical, and molecular study of 2 cases with literature review.
  • Gastrointestinal stromal tumors (GIST) are rare in the vermiform appendix.
  • Here, we report 2 appendiceal gastrointestinal stromal tumors in a 78-year-old woman and a 72-year-old man with a history of endometrial adenocarcinoma and urinary bladder carcinoma, respectively.
  • Both gastrointestinal stromal tumors were incidental findings at surgery for appendicitis-like symptoms and on follow-up for bladder carcinoma, respectively.
  • Tumors were 5 and 25 mm and were located in the mid portion and the tip, respectively.
  • The larger gastrointestinal stromal tumor was pedunculated.
  • We suggest that the molecular pathogenesis of appendiceal gastrointestinal stromal tumors beyond initiating KIT mutations might be different from their gastric and intestinal counterparts.
  • The coincidence of loss of p16 and overexpression of human telomerase reverse transcriptase seems to be in contradiction to the small size, the benign nature, and the limited growth potential of appendiceal gastrointestinal stromal tumors.
  • [MeSH-major] Appendiceal Neoplasms / pathology. Gastrointestinal Stromal Tumors / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18547614.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 21
  •  go-up   go-down


36. Kiziltaş S, Yorulmaz E, Bilir B, Enç F, Tuncer I: A remarkable intestinal lipoma case. Ulus Travma Acil Cerrahi Derg; 2009 Jul;15(4):399-402

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A remarkable intestinal lipoma case.
  • The small intestine was resected.
  • In conclusion, benign tumors of the small intestine, including intestinal lipomas, should be considered during the diagnostic process of clinical ileus and anemia.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Lipoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19669973.001).
  • [ISSN] 1306-696X
  • [Journal-full-title] Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES
  • [ISO-abbreviation] Ulus Travma Acil Cerrahi Derg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


37. Lok KH, Lai L, Yiu HL, Szeto ML, Leung SK: Endosonographic surveillance of small gastrointestinal tumors originating from muscularis propria. J Gastrointestin Liver Dis; 2009 Jun;18(2):177-80
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endosonographic surveillance of small gastrointestinal tumors originating from muscularis propria.
  • INTRODUCTION: Submucosal tumors (SMT) are not uncommonly found during upper endoscopy.
  • Management for small SMT originating from muscularis propria (MP) is controversial.
  • We report our experience in using EUS to monitor these tumors.
  • Patients with large tumors (maximal diameter > 3 cm), heterogeneous echo pattern, presence of cystic spaces or irregular extra-luminal margin were offered surgery in view of malignant risk.
  • Patients with small tumor and benign EUS features were offered regular EUS surveillance or surgery if they wished.
  • Forty-nine patients had a small tumor and benign EUS features.
  • The histopathological results were low risk gastrointestinal stromal tumor (GIST) in both patients.
  • Three patients (13.0%) showed interval increase in tumor size.
  • CONCLUSION: It remains unclear whether EUS surveillance for small tumors originating from MP in the upper gastrointestinal tract is useful.
  • [MeSH-major] Duodenal Neoplasms / ultrasonography. Endosonography. Esophageal Neoplasms / ultrasonography. Gastrointestinal Stromal Tumors / ultrasonography. Stomach Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Gastric Mucosa / ultrasonography. Humans. Intestinal Mucosa / ultrasonography. Male. Middle Aged. Retrospective Studies. Time Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19565047.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


38. Ammori BJ, El-Dhuwaib Y, Ballester P, Augustine T: Laparoscopic distal pancreatectomy for neuroendocrine tumors of the pancreas. Hepatogastroenterology; 2005 Mar-Apr;52(62):620-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic distal pancreatectomy for neuroendocrine tumors of the pancreas.
  • Although neuroendocrine tumors of the pancreas are traditionally managed by laparotomy, these rare neoplasms may be amenable to laparoscopic surgical resection.
  • Two female patients aged 63 and 69 years presented with clinical and biochemical features of an insulinoma and a vasoactive intestinal peptide secreting tumor (VIPoma), and were found on cross-sectional imaging to have 1.2-cm and 4.5-cm solitary tumors in the tail of the pancreas.
  • Histology revealed a benign insulinoma and a malignant VIPoma with lymph node metastases respectively.
  • Laparoscopic distal pancreatectomy for neuroendocrine tumors of the pancreas may be accomplished safely, with preservation of the spleen and splenic vessels in benign disease, and with benefits to the patients in terms of postoperative recovery.
  • [MeSH-major] Insulinoma / surgery. Laparoscopy. Pancreatectomy. Pancreatic Neoplasms / surgery. Vipoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816491.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


39. Carter JT, Grenert JP, Rubenstein L, Stewart L, Way LW: Tumors of the ampulla of vater: histopathologic classification and predictors of survival. J Am Coll Surg; 2008 Aug;207(2):210-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumors of the ampulla of vater: histopathologic classification and predictors of survival.
  • BACKGROUND: The histology and clinical behavior of ampullary tumors vary substantially.
  • We speculated that this might reflect the presence of two kinds of ampullary adenocarcinoma: pancreaticobiliary and intestinal.
  • STUDY DESIGN: We analyzed patient demographics, presentation, survival (mean followup 44 months), and tumor histology for 157 consecutive ampullary tumors resected from 1989 to 2006.
  • RESULTS: There were 33 benign (32 adenomas and 1 paraganglioma) and 124 malignant (118 adenocarcinomas and 6 neuroendocrine) tumors.
  • Size of tumor did not predict survival, nor did cribriform/papillary features, dirty necrosis, apical mucin, or nuclear atypia.
  • Patients with pancreaticobiliary ampullary adenocarcinomas presented with jaundice more often than those with the intestinal kind (p = 0.01) and had worse survival.
  • CONCLUSIONS: In addition to other factors, tumor type (intestinal versus pancreaticobiliary) had a major effect on survival in patients with ampullary adenocarcinoma.
  • Intestinal ampullary adenocarcinomas behaved like their duodenal counterparts, but pancreaticobiliary ones were more aggressive and behaved like pancreatic adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Follow-Up Studies. Humans. Jaundice, Obstructive / mortality. Jaundice, Obstructive / pathology. Jaundice, Obstructive / surgery. Kaplan-Meier Estimate. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Retrospective Studies. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656049.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Palanivelu C, Rangarajan M, Senthilkumar R, Madankumar MV: Minimal access surgery for adult intussusception with subacute intestinal obstruction: a single center's decade-long experience. Surg Laparosc Endosc Percutan Tech; 2007 Dec;17(6):487-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal access surgery for adult intussusception with subacute intestinal obstruction: a single center's decade-long experience.
  • MATERIALS AND METHODS: Between 1996 and 2006, we have treated 12 adults with intussusception who presented with acute or subacute intestinal obstruction.
  • Two patients had colonic carcinoma, as the leading point and the rest were benign tumors.
  • [MeSH-minor] Adult. Female. Humans. Intestinal Neoplasms / complications. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097305.001).
  • [ISSN] 1530-4515
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Vereczkey I, Tóth E, Orosz Z: [Diagnostic problems of ovarian mucinous borderline tumors]. Magy Onkol; 2009 Jun;53(2):127-33
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic problems of ovarian mucinous borderline tumors].
  • About 15-20% of all ovarian epithelial neoplasms are of borderline type (or atypical proliferative or carcinoma of low malignant potential) and about 5-7% are mucinous type, which are the second most common type behind the serous borderline tumors.
  • The borderline tumor is a serious diagnostic and treatment problem both for the pathologists and for clinicians.
  • These tumors appeared to be intermediate in their histologic and prognostic features between the benign cystadenomas and clearly malignant carcinomas.
  • The borderline tumors occur most commonly in childbearing age, and show an indolent course.
  • To diagnose the intraepithelial carcinoma, to detect the microinvasion and the expansive invasion in a mucinous borderline tumor, to differentiate from the metastasis of colorectal tumors may be very problematic in the majority of the cases.
  • Eleven cases diagnosed as mucinous borderline ovarian tumor in our institute from 2000 to 2008 were reviewed.
  • Eight out of 11 were intestinal type while three were cervical (mullerian) type.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Biomarkers, Tumor / analysis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. CA-125 Antigen / analysis. Diagnosis, Differential. Female. GPI-Linked Proteins. Homeodomain Proteins / analysis. Humans. Keratin-20 / analysis. Keratin-7 / analysis. Membrane Glycoproteins / analysis. Middle Aged. Neoplasm Invasiveness. Prognosis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581178.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CDX2 protein, human; 0 / GPI-Linked Proteins; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7; 0 / Membrane Glycoproteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / mesothelin
  •  go-up   go-down


42. Guillen-Ahlers H, Suckow MA, Castellino FJ, Ploplis VA: Fas/CD95 deficiency in ApcMin/+ mice increases intestinal tumor burden. PLoS One; 2010 Feb 05;5(2):e9070
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fas/CD95 deficiency in ApcMin/+ mice increases intestinal tumor burden.
  • BACKGROUND: Fas, a member of the tumor necrosis family, is responsible for initiating the apoptotic pathway when bound to its ligand, Fas-L.
  • One of the main limitations of the Apc(Min/+) mouse model is that it only develops benign polyps.
  • However, Apc(Min/+)/Fas(lpr) mice presented with a dramatic increase in tumor burden relative to Apc(Min/+) mice and invasive lesions at advanced ages.
  • CONCLUSIONS/SIGNIFICANCE: This study demonstrated that imposition of a Fas deletion in an Apc(Min/+) background results in a more aggressive phenotype of the Apc(Min/+) mouse model, with more rapid development of invasive intestinal tumors and a decrease in Fas-L levels.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transplant Proc. 1998 Mar;30(2):538 [9532168.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):699-703 [9872321.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):59-62 [9892185.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1262-9 [10098769.001]
  • [Cites] Cell. 1999 Mar 19;96(6):857-68 [10102273.001]
  • [Cites] Curr Opin Cell Biol. 1999 Apr;11(2):255-60 [10209153.001]
  • [Cites] J Pathol. 1998 Nov;186(3):240-6 [10211111.001]
  • [Cites] Cancer J. 2004 Sep-Oct;10(5):280-7 [15530254.001]
  • [Cites] J Surg Res. 2005 Feb;123(2):302-11 [15680394.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7455-64 [16288292.001]
  • [Cites] Science. 2005 Dec 2;310(5753):1504-10 [16293724.001]
  • [Cites] J Gastroenterol. 2006 Nov;41(11):1053-63 [17160516.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4800-6 [17510409.001]
  • [Cites] Carcinogenesis. 2008 Jul;29(7):1421-7 [18499699.001]
  • [Cites] PLoS One. 2009;4(8):e6713 [19696929.001]
  • [Cites] Curr Biol. 1999 Dec 16-30;9(24):1441-7 [10607586.001]
  • [Cites] J Immunol. 2000 Feb 1;164(3):1277-85 [10640741.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1217-20 [10728678.001]
  • [Cites] J Exp Med. 2000 Apr 3;191(7):1209-20 [10748238.001]
  • [Cites] Nat Med. 2000 May;6(5):493-5 [10802692.001]
  • [Cites] Ann N Y Acad Sci. 2000 Jun;910:178-92; discussion 193-5 [10911913.001]
  • [Cites] Clin Exp Metastasis. 2000;18(5):423-8 [11467775.001]
  • [Cites] Mol Cell Biol. 2002 Jan;22(2):680-91 [11756562.001]
  • [Cites] Semin Oncol. 2002 Jun;29(3 Suppl 11):62-70 [12138399.001]
  • [Cites] Trends Biochem Sci. 2002 Sep;27(9):462-7 [12217521.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):762-77 [12612914.001]
  • [Cites] Cancer Cell. 2003 Oct;4(4):257-62 [14585353.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):71-8 [14708027.001]
  • [Cites] Cell. 2004 Jan 23;116(2):205-19 [14744432.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):519-23 [15193254.001]
  • [Cites] Br J Cancer. 2004 Nov 1;91(9):1718-25 [15494722.001]
  • [Cites] J Exp Med. 1981 Nov 1;154(5):1671-80 [6975351.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Cell. 1991 Jul 26;66(2):233-43 [1713127.001]
  • [Cites] Science. 1992 May 1;256(5057):668-70 [1350108.001]
  • [Cites] Cell. 1993 Dec 17;75(6):1169-78 [7505205.001]
  • [Cites] Cancer Res. 1995 May 1;55(9):1811-6 [7728743.001]
  • [Cites] Cell. 1995 Jun 2;81(5):727-36 [7774014.001]
  • [Cites] Nature. 1995 Aug 17;376(6541):599-602 [7637810.001]
  • [Cites] Nature. 1995 Oct 19;377(6550):576-7 [7566165.001]
  • [Cites] Nature. 1996 Feb 22;379(6567):682 [8602212.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Science. 1996 Nov 22;274(5291):1363-6 [8910274.001]
  • [Cites] Nat Med. 1997 Feb;3(2):165-70 [9018234.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2550-4 [9205051.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13862-7 [9391118.001]
  • (PMID = 20140201.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL073750; United States / NHLBI NIH HHS / HL / HL 73750
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Antigens, CD95; 0 / Fas Ligand Protein; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2816700
  •  go-up   go-down


43. Jeong WK, Park JW, Choi HS, Chang HJ, Jeong SY: Transanal endoscopic microsurgery for rectal tumors: experience at Korea's National Cancer Center. Surg Endosc; 2009 Nov;23(11):2575-9
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgery for rectal tumors: experience at Korea's National Cancer Center.
  • BACKGROUND: Transanal endoscopic microsurgery (TEM) is a minimally invasive alternative to transanal excision, enabling complete local excision of selected benign or malignant rectal tumors.
  • This study aimed to determine the surgical and oncologic results for rectal tumors excised by TEM.
  • METHODS: From November 2001 to October 2007, 45 patients underwent TEM for excision of adenoma (13 patients), carcinoid tumor (6 patients), and carcinoma (26 patients).
  • RESULTS: The median tumor distance from the anal verge was 7 cm (range, 3-15 cm), and the median tumor size was 17 mm (range, 2-60 mm).
  • No recurrence occurred for six patients with carcinoid tumors.
  • Histologic examination of the carcinomas showed pathologic tumor (pT) stage 0 (ypT0) in 2 patients, pT1 in 17 patients (including ypT1 in 1 patient), pT2 in 6 patients, and pT3 in 1 patient.
  • CONCLUSIONS: The TEM procedure is a safe and appropriate surgical treatment option for benign rectal tumors.
  • [MeSH-major] Anal Canal / surgery. Microsurgery / methods. Neoplasm Recurrence, Local / pathology. Proctoscopy / methods. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenoma / mortality. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Cancer Care Facilities. Carcinoid Tumor / mortality. Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Korea. Male. Middle Aged. Minimally Invasive Surgical Procedures / adverse effects. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Patient Selection. Postoperative Complications / diagnosis. Postoperative Complications / surgery. Reoperation. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19347399.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


44. Sudhakar MK, Neeta, Senthil, Ahamed A, John S, Aggarwal G: Gastro-intestinal stromal tumour--a case report. J Indian Med Assoc; 2006 May;104(5):266, 270
Hazardous Substances Data Bank. IRON, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastro-intestinal stromal tumour--a case report.
  • Gastro-intestinal stromal tumours are a heterogenous group of mesenchymal tumours mostly arising from the stomach and small intestine which may be benign or malignant.
  • Upper GI scopy showed a proliferative growth in periampullary region with the histopathology of the growth showed features of gastrointestinal stromal tumour.
  • [MeSH-major] Gastrointestinal Stromal Tumors / diagnosis
  • [MeSH-minor] Abdominal Pain. Adult. Blood Transfusion. Female. Folic Acid / therapeutic use. Humans. Intestinal Mucosa / pathology. Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / therapy. Iron / therapeutic use. Tomography, X-Ray Computed / methods

  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17058574.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid; E1UOL152H7 / Iron
  •  go-up   go-down


45. Papalambros A, Petrou A, Brennan N, Bramis K, Felekouras E, Papalambros E: GIST suture-line recurrence at a gastrojejunal anastomosis 8 years after gastrectomy: can GIST ever be described as truly benign? A case report. World J Surg Oncol; 2010;8:90
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GIST suture-line recurrence at a gastrojejunal anastomosis 8 years after gastrectomy: can GIST ever be described as truly benign? A case report.
  • We present the case of a 71 year old man with recurrence of a Gastro Intestinal Stromal Tumour (GIST) at the gastrojejunal anastomosis eight years following partial gastrectomy for a very small primary gastric GIST.
  • The histopathology was in keeping with a diagnosis of a gastric GIST with a <2 cm tumour, with <5 mitosis per 50/HPF, no signs of necrosis and invasion limited to the mucosa.
  • He subsequently underwent completion gastrectomy and the histology revealed a 0.8 cm GIST tumour composed of spindle cells with <5 mitosis per 50/HPF, tumor invasion into the submucosa and positive expression of c-kit and SMA.
  • The literature suggests that tumour size, mitotic rate and tumour site are the most important predictive factors of recurrence.
  • Additional features such as the presence of necrosis, local tumour invasion and positive resection margins, can also influence recurrence rates.
  • In this case the lesion was a gastric GIST, very small (<2 cm), had low proliferation rate (<5 mitosis/HPF), lacked necrosis and was limited to the mucosa.
  • This case highlights how even the most innocent GISTs can never be described as truly benign.
  • [MeSH-major] Gastrectomy / methods. Gastrointestinal Stromal Tumors / surgery. Jejunum / surgery. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Stomach / surgery. Stomach Neoplasms / surgery

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Compr Canc Netw. 2010 Apr;8 Suppl 2:S1-41; quiz S42-4 [20457867.001]
  • [Cites] Oncology. 2010;78(2):130-40 [20389135.001]
  • [Cites] Hepatogastroenterology. 2010 Jan-Feb;57(97):95-7 [20422880.001]
  • [Cites] Virchows Arch. 2010 Feb;456(2):111-27 [20165865.001]
  • [Cites] Chin Med J (Engl). 2010 Jan 20;123(2):131-6 [20137358.001]
  • [Cites] J Egypt Natl Canc Inst. 2008 Mar;20(1):80-9 [19847285.001]
  • [Cites] APMIS. 2009 Feb;117(2):73-86 [19239429.001]
  • [Cites] J Nippon Med Sch. 2008 Oct;75(5):306-11 [19023173.001]
  • [Cites] Am J Surg Pathol. 2008 Oct;32(10):1553-9 [18724245.001]
  • [Cites] Pol Arch Med Wewn. 2008 Apr;118(4):216-21 [18575421.001]
  • [Cites] Int J Cancer. 2005 Nov 1;117(2):289-93 [15900576.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):821-9 [15648083.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):52-68 [15613856.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Br J Surg. 2010 Dec;97(12):1854-9 [20730857.001]
  • (PMID = 20946677.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2965163
  •  go-up   go-down


46. Thakur ML, Devadhas D, Zhang K, Pestell RG, Wang C, McCue P, Wickstrom E: Imaging spontaneous MMTVneu transgenic murine mammary tumors: targeting metabolic activity versus genetic products. J Nucl Med; 2010 Jan;51(1):106-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging spontaneous MMTVneu transgenic murine mammary tumors: targeting metabolic activity versus genetic products.
  • Despite the great strides made in imaging breast cancer (BC) in humans, the current imaging modalities miss up to 30% of BC, do not distinguish malignant lesions from benign ones, and require histologic examinations for which invasive biopsy must be performed.
  • Annually in the United States, approximately 5.6 million biopsies find benign lesions.
  • RT-PCR on excised tumors determined VPAC1 expression, and histology ascertained the pathology.
  • RESULTS: Ten tumors were detected by PET.
  • Four tumors were detected both by (18)F-FDG and by (64)Cu-TP3805.
  • Additionally, 4 tumors were imaged with (64)Cu-TP3805 only.
  • These 8 tumors overexpressed VPAC1 receptors and were malignant by histology.
  • The 2 remaining tumors were visualized with (18)F-FDG only.
  • These tumors did not express the VPAC1 oncogene product and had benign histology.
  • The 2 benign tumors that did not express the VPAC1 receptor were not imaged. (64)Cu-TP3805 promises to have the potential for the early and accurate imaging of primary and metastatic BC.
  • [MeSH-major] Mammary Neoplasms, Experimental / metabolism. Mammary Neoplasms, Experimental / radionuclide imaging. Organometallic Compounds. Pituitary Adenylate Cyclase-Activating Polypeptide. Radiopharmaceuticals / chemical synthesis. Receptors, Vasoactive Intestinal Polypeptide, Type I / biosynthesis
  • [MeSH-minor] Animals. Chromatography, High Pressure Liquid. Female. Fluorodeoxyglucose F18 / pharmacokinetics. Half-Life. Humans. Image Processing, Computer-Assisted. Mammary Tumor Virus, Mouse / genetics. Mice. Positron-Emission Tomography. Quality Control. Reverse Transcriptase Polymerase Chain Reaction. Tomography, X-Ray Computed

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20008985.001).
  • [ISSN] 1535-5667
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA- S10RR 023709; United States / NCI NIH HHS / CA / CA-RO1-109231; United States / NIBIB NIH HHS / EB / EB-RO1-001809; United States / NCI NIH HHS / CA / P30 CA56036; United States / PHS HHS / / RP-RO1-023709
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organometallic Compounds; 0 / Pituitary Adenylate Cyclase-Activating Polypeptide; 0 / Radiopharmaceuticals; 0 / Receptors, Vasoactive Intestinal Polypeptide, Type I; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


47. Ponsaing LG, Hansen MB: Therapeutic procedures for submucosal tumors in the gastrointestinal tract. World J Gastroenterol; 2007 Jun 28;13(24):3316-22
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic procedures for submucosal tumors in the gastrointestinal tract.
  • This review is part three of three and will present an update on the therapeutic options and procedures concerning gastrointestinal (GI) submucosal tumors (SMTs).
  • The aim of this paper is to investigate the treatments of GI SMTs and to present a case of a gastrointestinal stromal tumor (GIST).
  • The choice of treatment of localized tumors is endoscopic resection if possible or, alternatively, laparoscopic resection or surgical resection by an open procedure.
  • However, benign SMTs should only be excised if symptoms are present, and GISTs should be treated with particular precautions.
  • [MeSH-major] Gastrointestinal Neoplasms / therapy
  • [MeSH-minor] Benzamides. Endoscopy, Gastrointestinal. Female. Gastric Mucosa / pathology. Gastrointestinal Stromal Tumors / therapy. Humans. Imatinib Mesylate. Intestinal Mucosa / pathology. Middle Aged. Piperazines / therapeutic use. Pyrimidines / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17659670.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 58
  • [Other-IDs] NLM/ PMC4172711
  •  go-up   go-down


48. Fukuta N, Kitano M, Maekawa K, Chikugo T, Kudo M: Estimation of the malignant potential of gastrointestinal stromal tumors: the value of contrast-enhanced coded phase-inversion harmonics US. J Gastroenterol; 2005 Mar;40(3):247-55
Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimation of the malignant potential of gastrointestinal stromal tumors: the value of contrast-enhanced coded phase-inversion harmonics US.
  • The contrast-enhanced US with Levovist permits evaluation of the intratumoral vascularity of hepatic and pancreatic tumors and is useful for their differential diagnosis.
  • The purpose of the present study was to assess tumor vessels and the parenchymal flow of gastrointestinal stromal tumors (GISTs) by contrast-enhanced coded phase-inversion harmonic US and to evaluate whether vascularity is related to the malignant grade of the GISTs.
  • Tumors were observed in a real-time fashion of contrast-enhanced coded phase-inversion harmonic US after the injection of Levovist (400 mg/ml).
  • The vascular patterns were compared with tumor size, histological diagnosis, KIT mutations, and clinical findings such as metastasis.
  • RESULTS: The contrast-enhanced US images of the GISTs were classified into two types according to the blood flow area of the tumors as seen by real-time continuous imaging of the tumor vessels.
  • The image pattern "Poor" represented vessels flowing only in the peripheral part of the tumor, and "Rich" represented abundant vessels flowing from the periphery to the central part of the tumor.
  • Based on the final diagnosis, all tumors with "Poor" images were determined to be benign GISTs, and the rest tumors except one with "Rich" images were determined to be malignant GISTs.
  • [MeSH-major] Contrast Media. Gastrointestinal Stromal Tumors / blood supply. Neovascularization, Pathologic / ultrasonography. Polysaccharides
  • [MeSH-minor] Blood Flow Velocity / physiology. DNA, Neoplasm / genetics. Female. History, 17th Century. History, 18th Century. Humans. Infant, Newborn. Injections, Intravenous. Intestinal Mucosa / immunology. Intestinal Mucosa / pathology. Male. Microbubbles. Mutation. Neoplasm Staging / methods. Polymerase Chain Reaction. Proto-Oncogene Proteins c-kit / genetics. Retrospective Studies. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Gastroenterol. 2005 Mar;40(3):320-1 [15830297.001]
  • (PMID = 15830283.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Historical Article; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contrast Media; 0 / DNA, Neoplasm; 0 / Polysaccharides; 127279-08-7 / SHU 508; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


49. Lin CY, Chen HY, Jwo SC, Chan SC: Ileal angiomyolipoma as an unusual cause of small-intestinal intussusception. J Gastroenterol; 2005 Feb;40(2):200-3
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ileal angiomyolipoma as an unusual cause of small-intestinal intussusception.
  • Angiomyolipomas are benign mesenchymal tumors, but those that arise from the small intestine are exceedingly rare.
  • Small-bowel intussusception was shown on an abdominal computed tomography (CT) scan.
  • We discuss the clinical manifestations and clinicopathological and immunohistochemical findings of this benign tumor which appeared in this rare location.
  • [MeSH-major] Angiomyolipoma / complications. Ileal Neoplasms / complications. Intussusception / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15770405.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Desmin
  •  go-up   go-down


50. Kala Z, Válek V, Kysela P, Svoboda T: A shift in the diagnostics of the small intestine tumors. Eur J Radiol; 2007 May;62(2):160-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A shift in the diagnostics of the small intestine tumors.
  • Primary, secondary, benign or malignant tumorous diseases of the small intestine are rare.
  • METHODOLOGY: A retrospective study comprising 96 patients having undergone surgery for a small intestine tumor in our hospital from 1996 to 2005 is presented.
  • In the year 1998 we changed our philosophy in trying to directly detect the small intestine pathology and not making the diagnosis by the exclusion only.
  • Intestinal ultrasound was performed on the Ultramark 3000 HDI device with autofocussable convex 5 MHz and linear 7.5 MHz probes or nowadays ATL 5000 HDI, 7-12 MHz linear probe.
  • RESULTS: We treated surgically 96 patients with the small intestine tumor.
  • CONCLUSION: The small bowel ultrasound can be recommended as the first choice method.
  • All patients with even very moderate abdominal symptoms ought to be examined for the small intestine pathology.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / surgery. Intestine, Small / pathology. Intestine, Small / surgery
  • [MeSH-minor] Abdomen, Acute / etiology. Abdomen, Acute / surgery. Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Aged. Algorithms. Carcinoid Tumor / diagnosis. Carcinoid Tumor / surgery. Czech Republic. Endoscopy, Gastrointestinal. Endosonography. Female. Follow-Up Studies. Gastrointestinal Hemorrhage / etiology. Humans. Laparoscopy. Lymphoma / diagnosis. Lymphoma / surgery. Male. Melanoma / diagnosis. Melanoma / surgery. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17344005.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


51. Kimchi NA, Eliakim R, Suissa A, Scapa E: [The contribution of capsule endoscopy to the diagnosis of small-bowel tumors in cases of obscure overt gastrointestinal bleeding]. Harefuah; 2006 Nov;145(11):811-4, 862, 861
MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The contribution of capsule endoscopy to the diagnosis of small-bowel tumors in cases of obscure overt gastrointestinal bleeding].
  • BACKGROUND: The source of obscure bleeding is usually located in the small bowel.
  • GOALS: To review our experience with the diagnosis of small bowel tumors by CE in patients with obscure overt gastrointestinal bleeding.
  • RESULTS: Among 156 patients who underwent CE examination (including 58 patients with obscure overt bleeding), five patients, all of whom presented with melena, were diagnosed as having a small bowel tumor.
  • Three tumors were found in one patient (two ileal carcinoids and one ileal benign stromal tumor).
  • A jejunal benign stromal tumor was diagnosed in two other patients by push enteroscopy.
  • In two patients, three small tumors were detected, beyond the reach of push enteroscopy, but surgical confirmation was not available.
  • No tumors were found among patients in whom the indication for CE examination was not obscure overt bleeding.
  • CONCLUSIONS: The possibility of finding a small bowel tumor emphasizes the role of capsule endoscopy in patients with obscure overt gastrointestinal bleeding.
  • [MeSH-major] Capsule Endoscopy / methods. Gastrointestinal Hemorrhage / etiology. Intestinal Neoplasms / diagnosis
  • [MeSH-minor] Aged. Female. Humans. Jejunal Neoplasms / diagnosis. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17183952.001).
  • [ISSN] 0017-7768
  • [Journal-full-title] Harefuah
  • [ISO-abbreviation] Harefuah
  • [Language] heb
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


52. Bailey AA, Debinski HS, Appleyard MN, Remedios ML, Hooper JE, Walsh AJ, Selby WS: Diagnosis and outcome of small bowel tumors found by capsule endoscopy: a three-center Australian experience. Am J Gastroenterol; 2006 Oct;101(10):2237-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and outcome of small bowel tumors found by capsule endoscopy: a three-center Australian experience.
  • OBJECTIVE: The objective of the study was to examine diagnosis and outcome in a series of patients with small bowel tumors detected by capsule endoscopy (CE) in three Australian centers.
  • METHODS: Review of prospectively collected data from 416 CEs identified 27 tumors in 26 patients.
  • Clinical parameters, tumor histology, and follow-up are reported.
  • RESULTS: Twenty-seven tumors were identified in 26 patients (mean age 61 +/- 13.7 yr).
  • Indications for CE were obscure gastrointestinal (GI) bleeding (21), suspected tumor (3), abdominal pain (1), diarrhea (1).
  • Nine tumors were proven benign: hamartoma (4), cystic lymphangioma (1), primary amyloid (1), lipoma (1).
  • Seventeen tumors were malignant: five adenocarcinomas, six carcinoids, two melanoma metastases, two gastrointestinal stromal tumors (GIST), one colon carcinoma metastasis, one non-Hodgkin's lymphoma.
  • Tumors were surgically resected in 23 patients.
  • Three of the six with carcinoid tumors have had no recurrence up to 51 months postresection.
  • CONCLUSIONS: Small bowel tumors are a significant finding at CE and are often missed by other methods of investigation.
  • In many patients, detection of a tumor alters management and improves outcome.
  • [MeSH-major] Capsule Endoscopy. Intestinal Neoplasms / pathology. Intestinal Neoplasms / therapy. Intestine, Small

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17032187.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


53. Nishihara E, Miyauchi A, Hirokawa M, Kudo T, Ohye H, Ito M, Kubota S, Fukata S, Amino N, Kuma K: Benign thyroid teratomas manifest painful cystic and solid composite nodules: three case reports and a review of the literature. Endocrine; 2006 Oct;30(2):231-6
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign thyroid teratomas manifest painful cystic and solid composite nodules: three case reports and a review of the literature.
  • Benign thyroid teratomas are rare in adolescents and adults.
  • We report on three cases of benign thyroid teratomas that presented as painful tumors in the neck after puberty.
  • The tumor adjacent to the thyroid in each case showed rapid enlargement with predominant cystic lesions within several months.
  • Ultrasonography and computed tomography revealed few findings suggesting the origin of the tumor.
  • Cytological examination and culture of the aspirate failed to show cells originating from the thyroid or infectious findings, but revealed a small population of columnar epithelial cells or squamous epithelial cells.
  • The patients subsequently underwent resection of the tumor, and microscopic examination revealed various types of tissue including pancreas, adipose, cartilage, muscle, and skin, and the cystic wall was lined by gastric, intestinal, respiratory, and stratified squamous epithelium.
  • Surgical resection was curative, and subsequent histologic examination revealed mature benign teratomas of the thyroid.
  • The main characteristic of our cases presented the painful tumors due to the enlarged cystic formation lined by a variety of different types of epithelium, which agreed with previous cases of benign thyroid teratomas in adolescents and adults.
  • [MeSH-major] Pain / diagnosis. Teratoma / diagnosis. Thyroid Neoplasms / diagnosis. Thyroid Nodule / diagnosis
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17322585.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


54. Pasquali C, Sperti C, Lunardi C, Scappin S, Chierichetti F, Liessi G, Pedrazzoli S: [Positron emission tomography with fluorodeoxyglucose in gastro-entero-pancreatic tumors: diagnostic role and prognostic implications]. Suppl Tumori; 2005 May-Jun;4(3):S68-71
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Positron emission tomography with fluorodeoxyglucose in gastro-entero-pancreatic tumors: diagnostic role and prognostic implications].
  • From November 1994 to November 2004, seventy-seven patients with neuroendocrine gastro-entero-pancreatic tumor (71% pancreatic) were investigated with 18-fluorine-deoxi-glucose positron emission tomography (FDG-PET).
  • Overall PET sensitivity was 57%; 78% of malignant tumors, 67% of borderline and 17% of benign tumors were detected by FDG-PET.
  • No duodenal tumor was detected by PET scan.
  • In malignant neuroendocrine tumors PET positivity was related to short survival.
  • No patient with malignant tumor died for disease progression in the follow-up when PET was negative, while 13/35 PET positive patients died (p <0.003).
  • FDG-PET proved to be a second line technique in neuroendocrine digestive tumors.
  • [MeSH-major] Fluorodeoxyglucose F18. Intestinal Neoplasms / radionuclide imaging. Pancreatic Neoplasms / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals. Stomach Neoplasms / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437910.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


55. Levin TG, Powell AE, Davies PS, Silk AD, Dismuke AD, Anderson EC, Swain JR, Wong MH: Characterization of the intestinal cancer stem cell marker CD166 in the human and mouse gastrointestinal tract. Gastroenterology; 2010 Dec;139(6):2072-2082.e5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of the intestinal cancer stem cell marker CD166 in the human and mouse gastrointestinal tract.
  • BACKGROUND & AIMS: CD166 (also called activated leukocyte cell adhesion molecule [ALCAM]) is a marker of colorectal cancer (CRC) stem cells; it is expressed by aggressive tumors.
  • Although the presence of CD166 at the tumor cell surface has been correlated with shortened survival, little is known about its function and expression in normal intestinal epithelia.
  • METHODS: We characterized the expression pattern of CD166 in normal intestinal tissue samples from humans and mice using immunohistochemisty, flow cytometry, and quantitative reverse-transcriptase polymerase chain reaction.
  • Human and mouse intestinal tumors were also analyzed.
  • RESULTS: CD166 was expressed on the surface of epithelial cells within the stem cell niche and along the length of the intestine; expression was conserved across species.
  • In the small intestine, CD166 was observed on crypt-based Paneth cells and intervening crypt-based columnar cells (putative stem cells).
  • CD166 was located in the cytoplasm and at the surface of cells within human CRC tumors.
  • CD166-positive cells were also detected in benign adenomas in mice; rare cells coexpressed CD166 and CD44 or epithelial-specific antigen.
  • CONCLUSIONS: CD166 is highly expressed within the endogenous intestinal stem cell niche.
  • CD166-positive cells appear at multiple stages of intestinal carcinoma progression, including benign and metastatic tumors.
  • Further studies should investigate the function of CD166 in stem cells and the stem cell niche, which might have implications for normal intestinal homeostasis.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • [Cites] J Exp Med. 1995 Jun 1;181(6):2213-20 [7760007.001]
  • [Cites] Differentiation. 2003 Jan;71(1):28-41 [12558601.001]
  • [Cites] Am J Pathol. 1998 Mar;152(3):805-13 [9502422.001]
  • [Cites] J Bone Miner Res. 1998 Apr;13(4):655-63 [9556065.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):895-902 [14737120.001]
  • [Cites] Eur J Immunol. 2004 Apr;34(4):930-40 [15048703.001]
  • [Cites] J Clin Pathol. 2004 Nov;57(11):1160-4 [15509676.001]
  • [Cites] Science. 1976 Oct 1;194(4260):23-8 [959840.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Exp Cell Res. 1992 Nov;203(1):91-9 [1426054.001]
  • [Cites] J Biol Chem. 1993 Aug 25;268(24):18345-58 [8349710.001]
  • [Cites] J Neurobiol. 1994 Jul;25(7):831-45 [8089660.001]
  • [Cites] J Exp Med. 1995 Apr 1;181(4):1563-8 [7535342.001]
  • [Cites] J Cell Biol. 1998 May 4;141(3):765-77 [9566975.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55315-23 [15496415.001]
  • [Cites] J Cell Sci. 2005 Apr 1;118(Pt 7):1515-25 [15769845.001]
  • [Cites] Oncology. 2005;68(4-6):462-70 [16024937.001]
  • [Cites] Nature. 2006 Jan 5;439(7072):84-8 [16397499.001]
  • [Cites] J Clin Pathol. 2006 Apr;59(4):403-9 [16484444.001]
  • [Cites] FEBS Lett. 2006 May 15;580(11):2637-45 [16650408.001]
  • [Cites] J Immunol. 2006 Jul 15;177(2):877-84 [16818742.001]
  • [Cites] Med Sci Monit. 2006 Aug;12(8):BR263-73 [16865058.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):102-7 [17143262.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Development. 2007 Apr;134(8):1491-7 [17344225.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63 [17548814.001]
  • [Cites] Mol Cancer Ther. 2007 Oct;6(10):2737-46 [17938267.001]
  • [Cites] Nature. 2007 Oct 25;449(7165):1003-7 [17934449.001]
  • [Cites] Science. 2008 Jan 18;319(5861):336-9 [18202291.001]
  • [Cites] Nat Immunol. 2008 Feb;9(2):137-45 [18157132.001]
  • [Cites] Nat Cell Biol. 2008 Mar;10(3):353-60 [18264089.001]
  • [Cites] Stem Cells. 2008 Mar;26(3):630-7 [18055444.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1726-33 [18347173.001]
  • [Cites] Cell Death Differ. 2008 Jun;15(6):947-58 [18259194.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):48-53 [18356041.001]
  • [Cites] PLoS One. 2008;3(6):e2428 [18560594.001]
  • [Cites] Nat Genet. 2008 Jul;40(7):915-20 [18536716.001]
  • [Cites] BMC Gastroenterol. 2008;8:57 [19055726.001]
  • [Cites] Cell. 2009 Mar 6;136(5):903-12 [19269367.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3382-9 [19336570.001]
  • [Cites] Cell Stem Cell. 2009 May 8;4(5):427-39 [19427292.001]
  • [Cites] Nature. 2009 May 14;459(7244):262-5 [19329995.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2010 May;298(5):G590-600 [20185687.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):769-74 [10702391.001]
  • [Cites] Cancer Metastasis Rev. 2000;19(3-4):I-XI, 193-383 [11394186.001]
  • [Cites] Blood. 2001 Oct 1;98(7):2134-42 [11568000.001]
  • [Cites] J Exp Med. 2002 Jun 17;195(12):1549-63 [12070283.001]
  • [Cites] Prostate. 2003 Jan 1;54(1):34-43 [12481253.001]
  • [Cites] Blood. 1997 Apr 15;89(8):2706-16 [9108388.001]
  • (PMID = 20826154.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA118235; United States / NIDDK NIH HHS / DK / U01 DK085525-02; United States / NHLBI NIH HHS / HL / T32 HL007781; United States / NCI NIH HHS / CA / CA106195-06A1; United States / NCI NIH HHS / CA / CA118235-05; United States / NICHD NIH HHS / HD / T32 HD049309-05; United States / NCI NIH HHS / CA / CA106195; United States / NCI NIH HHS / CA / T32 CA106195; United States / NICHD NIH HHS / HD / HD049309; United States / NICHD NIH HHS / HD / T32 HD049309; United States / NCI NIH HHS / CA / T32 CA106195-06A1; United States / NHLBI NIH HHS / HL / T32 HL007781-14; United States / NIDDK NIH HHS / DK / R01 DK068326; United States / NCI NIH HHS / CA / CA118235; United States / NIDDK NIH HHS / DK / R01 DK068326-05; United States / NIDDK NIH HHS / DK / DK068326; United States / NIDDK NIH HHS / DK / DK085525-02; United States / NICHD NIH HHS / HD / HD049309-05; United States / NHLBI NIH HHS / HL / HL007781-14; United States / NHLBI NIH HHS / HL / HL007781; United States / NIDDK NIH HHS / DK / U01 DK085525; United States / NIDDK NIH HHS / DK / DK085525; United States / NIDDK NIH HHS / DK / DK068326-05; United States / NCI NIH HHS / CA / R01 CA118235-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ALCAM protein, human; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules, Neuronal; 0 / Fetal Proteins
  • [Other-IDs] NLM/ NIHMS234467; NLM/ PMC2997177
  •  go-up   go-down


56. Ferrarese F, Cecere V: [Gastro-intestinal stromal tumours (GISTs): prognostic and therapeutic features]. G Chir; 2006 May;27(5):205-8
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastro-intestinal stromal tumours (GISTs): prognostic and therapeutic features].
  • The biological behaviour is only hypothetical, according to the duration of symptomatology, the site and size of the tumour, the presence of hemorrhagic or necrotic areas, the cytological modifications and, above all, the number of mytosis: 5 mytosis x 50 HPF are considered significant for malignancy.
  • In the benign GISTs (26 pts) we have reported early mortality only in 5 cases; in the borderline forms (6 pts), in 4 rapidly evolving cases, the tumour had > 5 cm in size and the mytosis were > 5 x 50 HPF.
  • [MeSH-major] Gastrointestinal Stromal Tumors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16857107.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


57. Khoury T, Chadha K, Javle M, Donohue K, Levea C, Iyer R, Okada H, Nagase H, Tan D: Expression of intestinal trefoil factor (TFF-3) in hepatocellular carcinoma. Int J Gastrointest Cancer; 2005;35(3):171-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of intestinal trefoil factor (TFF-3) in hepatocellular carcinoma.
  • BACKGROUND: Trefoil peptides (TFF-1, 2, 3) are a family of protease-resistant regulatory factors that play a role in mucosal restitution, angiogenesis, apoptosis, and tumor progression.
  • Intestinal trefoil peptide (TFF-3) expression has been demonstrated in benign hepatobiliary diseases, but there are limited data regarding its expression in HCC.
  • Tumor/ normal tissue interface was assessable in 21 cases; 11 cases expressed TFF-3 at the interface.
  • There was a strong correlation between tumor grade and TFF-3 expression, wherein poorly differentiated tumors had moderate/strong TFF-3 expression (p = 0.008).
  • CONCLUSION: TFF-3 is commonly expressed in HCC and its expression correlates with tumor grade.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Peptides / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16110118.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptides; 146046-78-8 / trefoil factor
  •  go-up   go-down


58. Pulitzer M, Xu R, Suriawinata AA, Waye JD, Harpaz N: Microcarcinoids in large intestinal adenomas. Am J Surg Pathol; 2006 Dec;30(12):1531-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcarcinoids in large intestinal adenomas.
  • Composite adenoma-carcinoid tumors are rare colorectal lesions consisting of intermingled adenomatous and carcinoid components.
  • Unlike other mixed endocrine-glandular colorectal neoplasms, which are generally malignant, their glandular component is histologically benign and their natural history is favorable.
  • The patients' clinical course was benign on the basis of 2 years' median follow-up (range, 6 mo to 10 y).
  • Two patients with incomplete polypectomies underwent hemicolectomy revealing no residual endocrine neoplasia.
  • Awareness of microcarcinoids in colonic adenomas should help avert potential diagnostic pitfalls posed by their pleomorphism, basal location, and infiltrative patterns, and may help clarify their natural history and possible relationship to composite glandular-carcinoid tumors.
  • [MeSH-major] Adenoma / pathology. Carcinoid Tumor / pathology. Intestinal Neoplasms / pathology. Intestine, Large / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Female. Humans. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122508.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


59. Coco C, Rizzo G, Manno A, Mattana C, Verbo A: Surgical treatment of small bowel neoplasms. Eur Rev Med Pharmacol Sci; 2010 Apr;14(4):327-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of small bowel neoplasms.
  • Small intestinal neoplasms are uncommon cancers.
  • Benign small intestinal tumors (e.g., leiomyoma, lipoma, hamartoma, or desmoid tumor) usually are asymptomatic but may present with complications.
  • Primary malignancies of the small intestine, including adenocarcinoma, leiomyosarcoma, carcinoid, and lymphoma, are often symptomatic and may present with intestinal obstruction, jaundice, bleeding, or pain.
  • Metastatic neoplasms may involve the small intestine via contiguous spread, peritoneal metastases or hematogenous metastases.
  • Because the small intestine is relatively inaccessible to routine endoscopy, diagnosis of small intestinal neoplasms is often delayed for months after onset of symptoms.
  • During last years the increase of small bowel endoscopy and other diagnostic tools allow earlier non-operative diagnosis.
  • Even though radical resection of small bowel cancer plays an important role, the 5 yr overall survival remains low.
  • [MeSH-major] Intestinal Neoplasms / pathology. Intestinal Neoplasms / surgery. Intestine, Small / pathology. Intestine, Small / surgery
  • [MeSH-minor] Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Gastrointestinal Stromal Tumors / pathology. Gastrointestinal Stromal Tumors / surgery. Humans. Laparoscopy. Lymphoma / pathology. Lymphoma / surgery. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20496543.001).
  • [ISSN] 1128-3602
  • [Journal-full-title] European review for medical and pharmacological sciences
  • [ISO-abbreviation] Eur Rev Med Pharmacol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 51
  •  go-up   go-down


60. Tivadar B, Serban B, Mircea M, Tivadar B Jr, Leonard A, Daniela P, Simona M: Late hepatic metastasis in the evolution of gastrointestinal stromal tumors. Hepatogastroenterology; 2010 Jan-Feb;57(97):95-7
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late hepatic metastasis in the evolution of gastrointestinal stromal tumors.
  • Gastro-intestinal stromal tumours develop in the digestive tract wall, in the undifferentiated mesenchymal cells with a starting point at the level of the interstitial cells of Cajal.
  • Gastro-intestinal stromal tumours often lead to peritoneal and hepatic metastasis.
  • A special attention should be paid to localization, serosal invasion, mucous ulceration, size of the tumor and mitotic index, in order to set the prognosis of the patient.
  • We here by present two cases of gastro-intestinal stromal tumours one with gastric location and one jejunal tumor with ulceration and hemorrhage, of small sizes, initially diagnosed as benign but developing in the late evolution liver metastases.
  • [MeSH-major] Gastrointestinal Stromal Tumors / pathology. Jejunal Neoplasms / pathology. Leiomyoma / pathology. Liver Neoplasms / secondary. Stomach Neoplasms / pathology


61. Mehrabi A, Mood ZA, Roshanaei N, Fonouni H, Müller SA, Schmied BM, Hinz U, Weitz J, Büchler MW, Schmidt J: Mesohepatectomy as an option for the treatment of central liver tumors. J Am Coll Surg; 2008 Oct;207(4):499-509
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesohepatectomy as an option for the treatment of central liver tumors.
  • BACKGROUND: Despite substantial improvements in intra- and postoperative management of extended hemihepatectomy as the curative option for treatment of central liver tumors, the high morbidity and mortality rates accompanying the procedure still represent major obstacles.
  • STUDY DESIGN: Forty-eight consecutive patients (29 men and 19 women) with centrally located liver tumors underwent mesohepatectomy.
  • Indications for mesohepatectomy were liver metastasis (n = 29), hepatocellular carcinoma (n = 5), gallbladder carcinoma (n = 4), cholangiocellular carcinoma (n = 4), hemangioma (n = 2), and other benign diseases (n = 4).
  • Postoperative surgical complications were seen in 18.8% of patients (n = 9) and included liver failure (n = 1), intraabdominal abscess (n = 1), bilioma or bile leakage (n = 4), hemorrhage and hematoma (n = 2), peritonitis because of intestinal perforation (n = 1), and wound infection (n = 1).
  • Although it is a technically difficult operation and requires special attention to prevent surgical complications, it is justified in selected patients with centrally located tumors and is a feasible and safe alternative to extended liver resection.
  • [MeSH-major] Hepatectomy. Liver Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Am Coll Surg. 2010 Jun;210(6):1022. Mood, Zhoobin [corrected to Mood, Zhoobin A]
  • (PMID = 18926451.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Miettinen M, Kraszewska E, Sobin LH, Lasota J: A nonrandom association between gastrointestinal stromal tumors and myeloid leukemia. Cancer; 2008 Feb 1;112(3):645-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A nonrandom association between gastrointestinal stromal tumors and myeloid leukemia.
  • BACKGROUND: Gastrointestinal stromal tumors (GISTs) are KIT-positive mesenchymal tumors of the gastrointestinal tract that are driven by activated KIT-signalling or platelet-derived growth factor receptor-alpha (PDFGRA) signaling.
  • These tumors most commonly occur in the stomach and small intestine and encompass a clinical spectrum from benign to malignant.
  • BACKGROUND: Nine patients (2 with gastric GISTs and 7 with GISTs of the small intestine) developed myeloid leukemia.
  • All but 1 GIST case was found to have a low mitotic rate (0-1 per 50 high-power fields); however, tumor size varied from 3 to 18 cm (median, 4.5 cm).
  • [MeSH-major] Gastrointestinal Stromal Tumors / epidemiology. Intestinal Neoplasms / epidemiology. Leukemia, Myeloid / epidemiology. Stomach Neoplasms / epidemiology


63. Chang WC, Sheu BC, Lin MC, Chow SN, Huang SC: Carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian of borderline malignancy: a case report. Int J Gynecol Cancer; 2005 May-Jun;15(3):549-53
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian of borderline malignancy: a case report.
  • Epithelial ovarian tumors of borderline malignancy are tumors with histologic features and biologic behavior between benign and frankly malignant epithelial ovarian neoplasms.
  • Here, we present a 35-year-old patient with carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian tumor of borderline malignancy.
  • Total hysterectomy, bilateral salpingo-oophorectomy, appendectomy, and omentectomy were performed, and the frozen pathology during operation showed mucinous tumor of borderline malignancy of left ovary on April 18, 2002.
  • It is difficult to determine whether intestinal-type borderline mucinous tumors with intraepithelial carcinoma are associated with a worse prognosis compared with those with epithelial atypia alone due to disparate results in the published literature.
  • However, too few cases of carcinosarcoma-like mural nodule in mucinous tumor have been published to warrant a conclusion regarding their prognosis.
  • [MeSH-major] Carcinosarcoma / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Neoplasm Invasiveness. Prognosis

  • Genetic Alliance. consumer health - Ovarian carcinosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15882184.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Bruno M, Carucci P, Repici A, Pellicano R, Mezzabotta L, Goss M, Magnolia MR, Saracco GM, Rizzetto M, De Angelis C: The natural history of gastrointestinal subepithelial tumors arising from muscularis propria: an endoscopic ultrasound survey. J Clin Gastroenterol; 2009 Oct;43(9):821-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The natural history of gastrointestinal subepithelial tumors arising from muscularis propria: an endoscopic ultrasound survey.
  • AIM: The majority of lesions originating from muscularis propria of stomach, duodenum, and colon are gastrointestinal stromal tumors (GISTs).
  • Surgery is indicated when endosonographic criteria of malignancy are met, but little is known about the natural history of lesions with benign endosonographic features.
  • Aim of this study was to evaluate the natural course of benign-appearing lesions originating from muscularis propria in organs where GISTs significantly overcome leiomyomas.
  • MATERIALS AND METHODS: A total of 49 asymptomatic patients with hypoechoic lesions originating from the fourth layer of the gastrointestinal tract entered a follow-up program by means of endoscopic ultrasonography.
  • Surgical removal was proposed to all: 1 patient refused (she is still alive and symptom-free after 4 y), 3 of the 4 lesions removed proved to be GISTs with very low or low risk of malignancy and 1 lesion was classified as a glomus tumor with no malignant appearance.
  • CONCLUSIONS: Even small and benign-appearing lesions from muscularis propria may increase in size over time but this increase cannot be considered as an index of malignancy.
  • [MeSH-major] Endosonography. Gastric Mucosa / ultrasonography. Gastrointestinal Stromal Tumors / ultrasonography. Intestinal Mucosa / ultrasonography. Intestinal Neoplasms / ultrasonography. Stomach Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19349904.001).
  • [ISSN] 1539-2031
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Kianmanesh R, O'toole D, Sauvanet A, Ruszniewski P, Belghiti J: [Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors]. J Chir (Paris); 2005 May-Jun;142(3):132-49
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors].
  • Endocrine tumors (ET) of the digestive tract (formerly called neuroendocrine tumors) are rare.
  • They are classified into two principal types: gastrointestinal ET's (formerly called carcinoid tumors) which are the most common, and pancreaticoduodenal ET's.
  • The surgical goals are to: 1. prolong survival by resecting the primary tumor and any nodal or hepatic metastases, 2. control the symptoms related to hormonal secretion, 3. prevent or treat local complications.
  • The most common sites of gastrointestinal ET's ( carcinoids) are the appendix and the rectum; these are often small (<1 cm), benign, and discovered fortuitously at the time of appendectomy or colonoscopic removal.
  • Ileal ET's, even if small, are malignant, frequently multiple, and complicated in 30-50% of cases by bowel obstruction, mesenteric invasion, or bleeding.
  • Insulinoma and gastrinoma (cause of the Zollinger-Ellison syndrome) are the most common functional ET's. 80% are sporadic; in these cases, tumor size, location, and malignant potential determine the type of resection which may vary from a simple enucleation to a formal pancreatectomy.
  • In 10-20% of cases, pancreaticoduodenal ET presents in the setting of multiple endocrine neoplasia (NEM type I), an autosomal-dominant genetic disease with multifocal endocrine involvement of the pituitary, parathyroid, pancreas, and adrenal glands.
  • For gastrinoma with NEM-I, the benefit of surgical resection for tumors less than 2-3 cm in size is not clear.
  • The lesions are frequently small, multiple, and widespread and recurrence is frequent after excision.
  • [MeSH-major] Carcinoid Tumor / surgery. Carcinoma, Islet Cell / surgery. Carcinoma, Neuroendocrine / surgery. Insulinoma / surgery. Intestinal Neoplasms / surgery. Multiple Endocrine Neoplasia Type 1 / surgery. Pancreatic Neoplasms / surgery. Stomach Neoplasms / surgery. Zollinger-Ellison Syndrome / surgery
  • [MeSH-minor] Adult. Gastrinoma / diagnosis. Gastrinoma / surgery. Glucagonoma / diagnosis. Glucagonoma / surgery. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Malignant Carcinoid Syndrome / diagnosis. Malignant Carcinoid Syndrome / surgery. Multicenter Studies as Topic. Pancreatectomy. Postoperative Care. Postoperative Complications. Prognosis. Somatostatinoma / diagnosis. Somatostatinoma / surgery. Vipoma / diagnosis. Vipoma / surgery

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142076.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 236
  •  go-up   go-down


66. Lasota J, Wozniak A, Kopczynski J, Dansonka-Mieszkowska A, Wasag B, Mitsuhashi T, Sarlomo-Rikala M, Lee JR, Schneider-Stock R, Stachura J, Limon J, Miettinen M: Loss of heterozygosity on chromosome 22q in gastrointestinal stromal tumors (GISTs): a study on 50 cases. Lab Invest; 2005 Feb;85(2):237-47
Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of heterozygosity on chromosome 22q in gastrointestinal stromal tumors (GISTs): a study on 50 cases.
  • Mutational activation of KIT or PDGFRA is considered an early step in pathogenesis of gastrointestinal stromal tumors (GISTs); however, other nonrandom genetic changes have also been identified.
  • At least three common regions of deletions on chromosome 22q, which may harbor putative tumor suppressor genes, have been defined.
  • It has also been speculated that GI autonomous nerve tumors (GANTs), GISTs with ultrastructural features suggestive of autonomic nerve differentiation, are characterized by a specific deletion involving 22q13 cytogenetic region.
  • Four tumors were incidental minimal lesions <or=10 mm in diameter.
  • No NF2 mutations were identified in four analyzed tumors.
  • LOH on chromosome 22q was more frequent among intestinal than among gastric GISTs; however, there was no difference between LOH pattern seen in tumors defined by different histologic, ultrastructural (GANT) and molecular features (KIT and PDGFRA mutations).
  • Although minimal GISTs revealed LOH on chromosome 22q, there was a higher LOH frequency in malignant than in benign tumors.
  • An isolated LOH at D22S425 was equally found in both benign and malignant tumors.
  • These observations may suggest that LOHs on chromosome 22q in GISTs play a role in early stages of tumor formation as well as in late tumor progression.
  • [MeSH-major] Chromosomes, Human, Pair 22. Gastrointestinal Stromal Tumors / genetics. Loss of Heterozygosity

  • Genetic Alliance. consumer health - Chromosome 22q.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15580284.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


67. Kala Z, Kysela P, Meluzinova H: Small-bowel tumors in the elderly 65+ years: 10 years of experience. Z Gerontol Geriatr; 2008 Oct;41(5):403-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small-bowel tumors in the elderly 65+ years: 10 years of experience.
  • Primary, secondary, benign or malignant tumorous diseases of the small intestine are rare.
  • This work represents a prospective evaluation of a diagnostic and therapeutic algorithm in the management of the small-intestine tumor below the ligamentum Treitzi in patients over 65 years of age.
  • RESULTS: A population of 96 patients who underwent surgery for a small-intestinal tumor in our hospital from 1996 to 2006 is presented.
  • Ultrasound of the small intestine was sufficient to make the diagnosis in 21 of them.
  • CONCLUSION: The small-bowel ultrasound can be recommended as the first choice method.
  • All complaints regarding the gastrointestinal tract should be verified.
  • [MeSH-major] Intestinal Neoplasms / surgery. Intestinal Neoplasms / ultrasonography. Intestine, Small / surgery. Intestine, Small / ultrasonography. Ultrasonography / methods

  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18327695.001).
  • [ISSN] 0948-6704
  • [Journal-full-title] Zeitschrift für Gerontologie und Geriatrie
  • [ISO-abbreviation] Z Gerontol Geriatr
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 29
  •  go-up   go-down


68. Ha CY, Shah R, Chen J, Azar RR, Edmundowicz SA, Early DS: Diagnosis and management of GI stromal tumors by EUS-FNA: a survey of opinions and practices of endosonographers. Gastrointest Endosc; 2009 May;69(6):1039-44.e1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of GI stromal tumors by EUS-FNA: a survey of opinions and practices of endosonographers.
  • BACKGROUND: There is no consensus regarding the best management strategy for diagnosing and treating GI stromal tumors (GISTs).
  • A total of 92% use size as the main criterion to distinguish benign from malignant GISTs, and 90% refer lesions >5 cm for surgery.
  • [MeSH-major] Biopsy, Fine-Needle. Endosonography. Gastrointestinal Neoplasms / pathology. Gastrointestinal Neoplasms / ultrasonography. Gastrointestinal Stromal Tumors / pathology. Gastrointestinal Stromal Tumors / ultrasonography. Ultrasonography, Interventional
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Health Care Surveys. Humans. Internet. Intestinal Mucosa / pathology. Practice Patterns, Physicians'. Predictive Value of Tests. Proto-Oncogene Proteins c-kit / analysis. Referral and Consultation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastrointest Endosc. 2010 May;71(6):1102; author reply 1102-3 [20438905.001]
  • (PMID = 19410040.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


69. Sibio S, Borrini F, Sammartino P, Accarpio F, Biacchi D, Caprio G, Iafrate F, Baccheschi AM, Cornali T, Di Giorgio A: Predominant Brenner tumor combined with struma ovarii containing a papillary microcarcinoma associated with benign peritoneal strumosis: report of a case and histologic features. Endocr Pathol; 2010 Sep;21(3):199-203
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predominant Brenner tumor combined with struma ovarii containing a papillary microcarcinoma associated with benign peritoneal strumosis: report of a case and histologic features.
  • Brenner tumor and struma ovarii, two uncommon ovarian tumors arising alone or together with dermoid cysts or adenomas, are both rare entities.
  • Both tumors rarely become malignant and rarely metastasize.
  • Few published reports describe coexisting Brenner tumor and malignant struma ovarii.
  • The patient we describe, a 74-year-old woman, presented with a 2 months' history of lower abdominal pain and episodic intestinal subocclusion due to a complex pelvic mass.
  • The mass consisted predominantly of a Brenner tumor associated with struma ovarii containing a single small island of thyroid tissue that had undergone malignant transformation into a well-differentiated papillary carcinoma and also normal thyroid tissue that had spread to the peritoneum.
  • [MeSH-major] Brenner Tumor / pathology. Carcinoma, Papillary / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / secondary. Struma Ovarii / secondary
  • [MeSH-minor] Aged. Breast Neoplasms / complications. Carcinoma, Ductal, Breast / complications. Female. Humans. Neoplasms, Second Primary / pathology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20532676.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Hornick JL, Fletcher CD: Intestinal perineuriomas: clinicopathologic definition of a new anatomic subset in a series of 10 cases. Am J Surg Pathol; 2005 Jul;29(7):859-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal perineuriomas: clinicopathologic definition of a new anatomic subset in a series of 10 cases.
  • Benign peripheral nerve sheath tumors are uncommon in the gastrointestinal tract, and perineuriomas have not previously been reported to occur at this anatomic location.
  • In this study, we analyzed the clinicopathologic and immunohistochemical features of 10 perineuriomas arising in the intestine.
  • Eight of the lesions were intramucosal perineuriomas presenting as small sessile polyps detected during colonoscopy; 6 of these 8 patients were asymptomatic and undergoing colorectal cancer screening.
  • The colonic submucosal tumor was microscopically well circumscribed, whereas the jejunal perineurioma showed focal infiltration through the muscularis propria into the subserosa.
  • The stroma was collagenous in the colonic tumor and predominantly myxoid in the jejunal tumor.
  • All tumors except one were positive for epithelial membrane antigen (EMA); 4 of 10 expressed claudin-1 and 2 of 10 expressed CD34.
  • All tumors were negative for S-100 protein, glial fibrillary acidic protein, neurofilament protein, smooth muscle actin, desmin, caldesmon, KIT, and pan-keratin.
  • Electron microscopy was performed on the tumor lacking EMA expression, revealing typical features of perineurioma, namely, spindle cells with long bipolar cytoplasmic processes and prominent pinocytotic vesicles, surrounded by discontinuous basal lamina.
  • No tumor recurred.
  • In summary, perineuriomas may arise in the intestine, most often as intramucosal lesions detected as colorectal polyps with distinctive histologic features including entrapment of colonic crypts.
  • Distinguishing perineuriomas from other spindle cell neoplasms of the gastrointestinal tract can be facilitated by immunostaining for EMA and claudin-1.
  • [MeSH-major] Intestinal Neoplasms / pathology. Nerve Sheath Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Male. Microscopy, Electron, Transmission. Middle Aged. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2006 Oct;30(10):1337-9 [17001168.001]
  • (PMID = 15958849.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 26
  •  go-up   go-down


71. Agaimy A, Wünsch PH: Gastrointestinal stromal tumours: a regular origin in the muscularis propria, but an extremely diverse gross presentation. A review of 200 cases to critically re-evaluate the concept of so-called extra-gastrointestinal stromal tumours. Langenbecks Arch Surg; 2006 Aug;391(4):322-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ICCs form a network surrounding the myenteric plexus and between-muscle fibres of the muscularis propria of the tubular GI tract.
  • AIM AND METHODS: To study the diversity of gross presentation of GISTs and to critically assess the incidence of EGISTs and their relationship to mural GISTs, a total of 200 neoplasms with typical morphologic and immunohistochemical features of GISTs were reviewed, looking for any degree of association with the muscularis propria of the gut wall.
  • RESULTS: There were 130 gastric (65%), 9 duodenal (4.5%), 48 small intestinal (24%), 9 colorectal (4.5%), 1 appendiceal (0.5%) and 3 unclassifiable GISTs (1.5%).
  • After critical re-evaluation of surgical reports and remote clinical history and a careful search for residual muscular tissue from the gut wall in the tumour pseudocapsule (in some cases supported by desmin immunoreactivity), it was possible to reclassify most of these cases (11/14) as either GISTs with extensive extramural growth resulting in loss of contact to the external muscle coat of the gut (8/14) or as metastases from an inoperable GIST (2/14) or from a previously resected deceptively benign tumour (1/14).
  • In contrast to most other neoplasms, GISTs should be defined by virtue of any degree of association with the muscularis propria (no matter how minimal), but not by localisation of the bulk of the tumour.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16402273.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


72. Badea R, Ciobanu L, Gomotirceanu A, Hagiu C, Socaciu M: Contrast ultrasonography--a necessary procedure for a better characterization of digestive tract pathology. Med Ultrason; 2010 Mar;12(1):73-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contrast ultrasonography--a necessary procedure for a better characterization of digestive tract pathology.
  • The pathology of the digestive tract, extremely popular, with equal sex distribution, can have a clinical history of chronic illness or emergency.
  • Diagnosis is based on endoscopy (identifies the lesion, permits histological sample under visual control, and minimally invasive treatment for polypoid benign tumors).
  • Even so, the characteristics of the inflammatory diseases and the detection of tumors, particularly those with endoluminal development, can be difficult.
  • In recent years transabdominal ultrasound examination of the digestive tract was supplemented with more precise methods of investigation of the lumen and circulation of the intestinal wall.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21165458.001).
  • [ISSN] 1844-4172
  • [Journal-full-title] Medical ultrasonography
  • [ISO-abbreviation] Med Ultrason
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


73. Tamura H, Ohtsuka M, Washiro M, Kimura F, Shimizu H, Yoshidome H, Kato A, Seki N, Miyazaki M: Reg IV expression and clinicopathologic features of gallbladder carcinoma. Hum Pathol; 2009 Dec;40(12):1686-92
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Regenerating islet-derived family, member 4 (Reg IV) has been shown to be associated with colorectal carcinogenesis and gastric carcinogenesis through intestinal metaplasia.
  • Immunohistochemically, although only a small part of the epithelium with intestinal metaplasia in 2 of 4 cases with adenomyomatosis showed Reg IV expression, Reg IV was negative in all cases with normal gallbladder (n = 15) and cholelithiasis (n = 13).
  • Expression was more frequently observed in well to moderately differentiated than in poorly differentiated adenocarcinomas and significantly correlated with expression of caudal-related homeobox transcription factor (a candidate for involvement in the induction of intestinal metaplasia).
  • Before surgical resection, 4 (33%) of 12 patients with gallbladder carcinoma had high serum Reg IV levels, whereas Reg IV was never elevated in 12 patients with benign diseases.
  • The serum levels of Reg IV decreased after surgical resection of the tumors.
  • These results suggest that Reg IV is involved in gallbladder carcinoma carcinogenesis through intestinal metaplasia and is associated with relatively favorable prognosis in patients after surgery.
  • The serum level of Reg IV may be of use or indicative of neoplasia.
  • [MeSH-major] Adenocarcinoma / metabolism. Gallbladder Neoplasms / metabolism. Lectins, C-Type / biosynthesis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Enzyme-Linked Immunosorbent Assay. Gene Expression. Homeodomain Proteins / biosynthesis. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Metaplasia / genetics. Metaplasia / metabolism. Metaplasia / pathology. Neoplasm Staging. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19716164.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Lectins, C-Type; 0 / REG4 protein, human
  •  go-up   go-down


74. Fingleton B, Powell WC, Crawford HC, Couchman JR, Matrisian LM: A rat monoclonal antibody that recognizes pro- and active MMP-7 indicates polarized expression in vivo. Hybridoma (Larchmt); 2007 Feb;26(1):22-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunostaining of MMP-7 in normal tissues or benign tumors of intestinal, breast, and prostatic origin indicates that this protein is normally localized luminally in glandular epithelium.
  • The localization pattern would suggest that in normal or early stage tumors, MMP-7 is most likely not directly involved in extracellular matrix degradation.
  • In contrast, advanced colon tumors show MMP-7 in invading cells at the advancing edge of the tumor.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Differentiation. 2002 Dec;70(9-10):561-73 [12492497.001]
  • [Cites] Curr Biol. 1999 Dec 16-30;9(24):1441-7 [10607586.001]
  • [Cites] Cancer Cell. 2005 May;7(5):485-96 [15894268.001]
  • [Cites] Science. 1999 Oct 1;286(5437):113-7 [10506557.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1402-7 [9037065.001]
  • [Cites] Prostate. 1996 Sep;29(3):159-68 [8827084.001]
  • [Cites] Int J Biochem Cell Biol. 1996 Feb;28(2):123-36 [8729000.001]
  • [Cites] Protein Expr Purif. 1994 Feb;5(1):27-36 [8167471.001]
  • [Cites] Nat Rev Immunol. 2004 Aug;4(8):617-29 [15286728.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1423-47 [15131803.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):119-35 [15000153.001]
  • [Cites] Am J Pathol. 2003 Jun;162(6):1831-43 [12759241.001]
  • [Cites] Circ Res. 2003 May 2;92(8):827-39 [12730128.001]
  • [Cites] J Clin Invest. 2000 Jan;105(2):143-50 [10642592.001]
  • [Cites] J Clin Invest. 2002 Jun;109(11):1437-44 [12045257.001]
  • (PMID = 17316082.001).
  • [ISSN] 1554-0014
  • [Journal-full-title] Hybridoma (2005)
  • [ISO-abbreviation] Hybridoma (Larchmt)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA60867; United States / NCI NIH HHS / CA / R01 CA84360; United States / NIAMS NIH HHS / AR / AR36457; United States / NCI NIH HHS / CA / R01 CA084360; United States / NIAMS NIH HHS / AR / P30 AR48311; United States / NIAMS NIH HHS / AR / P30 AR048311; United States / NCI NIH HHS / CA / R01 CA100126; United States / NCI NIH HHS / CA / R01 CA060867
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Enzyme Precursors; EC 3.4.24.23 / Matrix Metalloproteinase 7
  • [Other-IDs] NLM/ NIHMS403810; NLM/ PMC3838102
  •  go-up   go-down


75. Bara T, Bancu S, Bara T Jr, Mureşan M, Bancu L, Azamfirei L, Podeanu D, Mureşan S: [Gastric stromal tumor with liver and subcutaneus metastasis. Case report]. Chirurgia (Bucur); 2009 Sep-Oct;104(5):621-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric stromal tumor with liver and subcutaneus metastasis. Case report].
  • The gastrointestinal stromal tumours expand from the undefine mezenchimal cells of the intestinal wall and the origin is in the Cajal interstitial cells.
  • Very importants factors for grading are the tumour localisation, the invasion of serosa or mucosa, the dimensions of tumour and the number of mytosis.
  • We present a case with haemoragic gastric stromal tumour, with small dimensions, which was initially diagnosed as a "benign" tumour.
  • CONCLUSIONS: The gastrointestinals stromal tumours represent a very rare group of digestive tract tumors, with malignant potentially evolution; the first choice of treatment is surgery, with complete ablation of the tumour.
  • [MeSH-major] Gastrointestinal Stromal Tumors / secondary. Liver Neoplasms / secondary. Soft Tissue Neoplasms / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19943565.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


76. Colombo P, Rahal D, Grizzi F, Quagliuolo V, Roncalli M: Localized intra-abdominal fibromatosis of the small bowel mimicking a gastrointestinal stromal tumor: a case report. World J Gastroenterol; 2005 Sep 7;11(33):5226-8
Genetic Alliance. consumer health - Fibromatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized intra-abdominal fibromatosis of the small bowel mimicking a gastrointestinal stromal tumor: a case report.
  • Intra-abdominal fibromatosis (IAF) is a benign mesenchymal lesion that can occur throughout the gastrointestinal tract.
  • Although rare, it is the most common primary tumor of the mesentery and can develop at any age.
  • We describe a rare case of primary IAF involving the mesentery and small bowel which clinically, macroscopically and histologically mimicked malignant gastrointestinal stromal tumor (GIST).
  • This report highlights the fact that benign IAF can be misdiagnosed as a malignant GIST localized in the mesentery or arising from the intestinal wall.
  • Their diagnostic discrimination is essential because of their very different biological behaviors and the fact that the introduction of effective therapies involving tyrosine kinase inhibitor STI571 (imatinib mesylate) has greatly changed the clinical approach to intra-abdominal stromal spindle cell tumors.
  • [MeSH-major] Fibromatosis, Abdominal / diagnosis. Gastrointestinal Stromal Tumors / diagnosis. Intestinal Neoplasms / diagnosis. Intestine, Small

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16127758.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4320401
  •  go-up   go-down


77. Schildhaus HU, Merkelbach-Bruse S, Binot E, Büttner R, Wardelmann E: [Inflammatory fibroid polyp: from Vanek's "submucosal granuloma" to the concept of submucosal mesenchymal neoplasia]. Pathologe; 2010 Mar;31(2):109-14
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inflammatory fibroid polyp: from Vanek's "submucosal granuloma" to the concept of submucosal mesenchymal neoplasia].
  • IFP represent polypous proliferations of spindle cells in the submucosa and mucosa of the stomach, small bowel and colon with inflammatory infiltration.
  • Therefore, IFP represent true benign mesenchymal tumors of the gastrointestinal tract.
  • [MeSH-major] Eosinophilic Granuloma / pathology. Gastrointestinal Neoplasms / pathology. Leiomyoma / pathology. Polyps / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / genetics. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. DNA Mutational Analysis. Diagnosis, Differential. Gastric Mucosa / pathology. Gastritis / pathology. Gastrointestinal Stromal Tumors / genetics. Gastrointestinal Stromal Tumors / pathology. Helicobacter Infections / genetics. Helicobacter Infections / pathology. Helicobacter pylori. Humans. Intestinal Mucosa / pathology. Receptor, Platelet-Derived Growth Factor alpha / genetics. Sequence Analysis, DNA. Sequence Analysis, Protein

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20107807.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  • [Number-of-references] 23
  •  go-up   go-down


78. Nguyen VX, Nguyen CC, Li B, Das A: Digital image analysis is a useful adjunct to endoscopic ultrasonographic diagnosis of subepithelial lesions of the gastrointestinal tract. J Ultrasound Med; 2010 Sep;29(9):1345-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Digital image analysis is a useful adjunct to endoscopic ultrasonographic diagnosis of subepithelial lesions of the gastrointestinal tract.
  • OBJECTIVE: The purpose of this study was to explore the role of digital image analysis in differentiating endoscopic ultrasonographic (EUS) features of potentially malignant gastrointestinal subepithelial lesions (SELs) from those of benign lesions.
  • METHODS: Forty-six patients with histopathologically confirmed gastrointestinal stromal tumors (GISTs), carcinoids, and lipomas who had undergone EUS evaluation were identified from our database.
  • [MeSH-major] Endosonography. Gastrointestinal Neoplasms / ultrasonography. Image Interpretation, Computer-Assisted / methods
  • [MeSH-minor] Area Under Curve. Carcinoid Tumor / pathology. Carcinoid Tumor / ultrasonography. Gastrointestinal Stromal Tumors / pathology. Gastrointestinal Stromal Tumors / ultrasonography. Humans. Intestinal Mucosa / pathology. Lipoma / pathology. Lipoma / ultrasonography. Neural Networks (Computer). Principal Component Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20733191.001).
  • [ISSN] 1550-9613
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Golubović G, Celeketić D, Kiurski M, Tomasević R, Stanković D, Pavlović A: [Leiomyomas and massive digestive hemorrhages--case reports of patients diagnosed in 2004]. Med Pregl; 2007 May-Jun;60(5-6):292-4
MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common location of these benign submucosal tumors is stomach, followed by small intestine and large intestine.
  • CASE REPORT: The most common symptoms of these patients were massive intestinal hemorrhage, with haematemesis and melaena.
  • Hemorrhages resulted from superficial lesions, caused by pressure of the tumour on the intestinal blood vessels.
  • DISCUSSION AND CONCLUSION: According to the literature data, gastrointestinal leiomyomas account for 20%-30% of all types of gastrointestinal tumors.
  • Our research revealed that the incidence of leiomyomas was significantly lower within our group of patients, accounting for 12% of all benign gastrointestinal tumors.
  • They were also the main cause of hemodynamic instability in our patients having massive and recurrent intestinal hemorrhages, which is not often seen in practice.
  • These tumors are often an accidental finding at autopsy, especially if they are smaller than 3 centimeters and not followed by consequential complications.
  • [MeSH-major] Gastrointestinal Hemorrhage / etiology. Gastrointestinal Neoplasms / complications. Leiomyoma / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988066.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


80. Park SB, Ha HK, Kim AY, Lee SS, Kim HJ, Park BJ, Jin YH, Park SH, Kim KW: The diagnostic role of abdominal CT imaging findings in adults intussusception: focused on the vascular compromise. Eur J Radiol; 2007 Jun;62(3):406-15
Hazardous Substances Data Bank. Barium sulfate .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intussusception is defined as telescoping of one segment of the gastrointestinal tract into an adjacent one.
  • More than 90% of patients with adult intussusception have been reported to have an organic cause, with benign or malignant tumors for accounting for approximately 65% of the cases.
  • Therefore, determination of the presence or absence of intestinal necrosis in intussusception is important in patient management.
  • On CT, the presence of well-known diagnostic CT criteria for strangulated obstruction (especially severe engorgement or twisting of the mesenteric vessels) as well as evidence of loss of the layered pattern, accumulation of extraluminal fluid collection, and bowel perforation, may suggest the diagnosis of intestinal necrosis.
  • However, CT and MR provide excellent pre-operative evaluation, including the possible extension and/or dissemination of a malignant tumor.
  • [MeSH-major] Intestinal Neoplasms / complications. Intestines / blood supply. Intestines / radiography. Intussusception / diagnosis. Radiography, Abdominal / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17412545.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media; 25BB7EKE2E / Barium Sulfate; 4419T9MX03 / Iohexol; 712BAC33MZ / iopromide; JR13W81H44 / Iopamidol
  •  go-up   go-down


81. Biermann K, Heukamp LC, Büttner R, Zhou H: Uterine tumor resembling an ovarian sex cord tumor associated with metastasis. Int J Gynecol Pathol; 2008 Jan;27(1):58-60
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine tumor resembling an ovarian sex cord tumor associated with metastasis.
  • Uterine tumors resembling ovarian sex-cord tumors (UTROSCT) are very rare, usually benign uterine tumors, and are probably derived from uterine mesenchymal stem cells.
  • Four years after a diagnosis of UTROSCT of the uterine corpus, the patient developed obstructive ileus due to a large infiltrating tumor within the small bowel with the same morphology and expression pattern as the previously diagnosed UTROSCT.
  • In addition, 2 benign gastrointestinal stromal tumors were detected in the same patient.
  • This case indicates that although the majority of UTROSCT are benign tumors, some of them might undergo malignant transformation and have a metastatic potency.
  • [MeSH-major] Intestinal Neoplasms / secondary. Ovarian Neoplasms / pathology. Sex Cord-Gonadal Stromal Tumors / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Female. Gastrointestinal Stromal Tumors / metabolism. Gastrointestinal Stromal Tumors / pathology. Humans. Immunohistochemistry. Intestinal Obstruction / etiology. Intestine, Small / metabolism. Intestine, Small / pathology. Neoplasms, Second Primary / metabolism. Neoplasms, Second Primary / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156976.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


82. Shah SN: Malignant gastrointestinal stromal tumor of intestine: a case report. Indian J Pathol Microbiol; 2007 Apr;50(2):357-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant gastrointestinal stromal tumor of intestine: a case report.
  • Smooth muscle tumors of the alimentary tract are uncommon.
  • Cancer of small intestine comprises less than 20% of all malignant tumors.
  • He was diagnosed as a case of acute intestinal obstruction and on laparotomy an extraluminal mass was found at jejunoileal junction.
  • Histopathology revealed a malignant gastrointestinal stromal tumor (GIST) which was confirmed by immunohistochemistry.
  • The case is reported with review of literature and criteria for differentiation between benign and malignant tumors are enumerated.
  • [MeSH-major] Gastrointestinal Stromal Tumors / pathology. Intestinal Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Ileal Neoplasms / pathology. Jejunal Neoplasms / pathology. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883072.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 13
  •  go-up   go-down


83. Merchant NB, Parikh AA, Kooby DA: Should all distal pancreatectomies be performed laparoscopically? Adv Surg; 2009;43:283-300
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are both enough experience and data (though retrospective) to confirm that LDP with or without spleen preservation appears to be a safe treatment for benign or noninvasive lesions of the pancreas.
  • Based on the fact that LDP can be performed with similar or shorter operative times, blood loss, complication rates, and length of hospital stay than ODP, it can be recommended as the treatment of choice for benign and noninvasive lesions in experienced hands when clinically indicated.
  • It is very difficult to make clear recommendations with regard to laparoscopic resection of malignant pancreatic tumors due to the lack of conclusive data.
  • Additional areas of discovery are in staple line reinforcement for left pancreatectomy and suturing technology for pancreatico-intestinal anastomosis.
  • Can we enucleate a small tumor off the pancreatic body by passing an endoscope through the gastric (or colonic) wall, and bring the specimen out via the mouth or anus?

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19845186.001).
  • [ISSN] 0065-3411
  • [Journal-full-title] Advances in surgery
  • [ISO-abbreviation] Adv Surg
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 95
  •  go-up   go-down


84. Sunada K, Yamamoto H: Technology and indications. Gastrointest Endosc Clin N Am; 2009 Jul;19(3):325-33
MedlinePlus Health Information. consumer health - Small Intestine Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Double-balloon endoscopy (DBE) was developed based on the principle of preventing stretching of the intestinal tract by anchoring the convoluted intestinal tract with an endoscope and overtube fitted with inflatable balloons.
  • The indications for DBE include the diagnosis or treatment of various small intestinal conditions such as obscure gastrointestinal bleeding, Crohn's disease, and benign and malignant tumors.
  • In addition, DBE can be used to approach the surgically modified intestinal tract; conventional endoscopes have difficulty in that situation.
  • [MeSH-major] Capsule Endoscopy. Duodenal Diseases / diagnosis. Gastrointestinal Hemorrhage / diagnosis. Ileal Diseases / diagnosis. Intestine, Small. Jejunal Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19647642.001).
  • [ISSN] 1558-1950
  • [Journal-full-title] Gastrointestinal endoscopy clinics of North America
  • [ISO-abbreviation] Gastrointest. Endosc. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


85. Jang JY, Park YC, Song YS, Lee SE, Hwang DW, Lim CS, Lee HE, Kim WH, Kim SW: Increased K-ras mutation and expression of S100A4 and MUC2 protein in the malignant intraductal papillary mucinous tumor of the pancreas. J Hepatobiliary Pancreat Surg; 2009;16(5):668-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased K-ras mutation and expression of S100A4 and MUC2 protein in the malignant intraductal papillary mucinous tumor of the pancreas.
  • PURPOSE: The purpose of this study was to document the biological changes during the progression of intraductal papillary mucinous neoplasm of the pancreas (IPMN) and to identify biological markers capable of differentiating benign and malignant IPMN.
  • The paraffin-embedded tumors from 27 with benign IPMNs and from 14 with IPMCs were subjected to immunohistochemical staining and DNA extraction.
  • RESULTS: K-ras mutations at codon 12 and 13 were detected in 13 of 37 (38.2%) of the IPMNs: in 5 of 24 (20.8%) of benign IPMNs, and in 8 of 13 (61.5%) of malignant IPMNs (p = 0.028).
  • S100A4 was expressed in 2 (7.4%) of 27 benign IPMNs, and 6 (42.9%) of 14 malignant IPMNs (p = 0.007).
  • MUC2 was expressed in 2 (7.4%) benign IPMNs, and in 9 (64.3%) malignant IPMNs (p < 0.001).
  • CONCLUSION: K-ras mutation and the expression of S100A4 and MUC2 (especially in intestinal subtype) were found to be related to malignancy in IPMN, and may be useful for the diagnosis and for assessing the biological behavior of IPMN.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Pancreatic Ductal / genetics. Mucin-2 / genetics. Pancreatic Neoplasms / genetics. S100 Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Aged. Aged, 80 and over. Biopsy, Needle. Cohort Studies. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Genes, ras. Humans. Immunohistochemistry. Male. Middle Aged. Mutation. Neoplasm Staging. Polymerase Chain Reaction. Probability. Prognosis. Retrospective Studies. Statistics, Nonparametric. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19412570.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-2; 0 / S100 Proteins
  •  go-up   go-down


86. McKenney JK, Soslow RA, Longacre TA: Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei. Am J Surg Pathol; 2008 May;32(5):645-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
  • Mucinous epithelial neoplasms arising in association with mature teratomas are a heterogeneous group of tumors, but with the exception of a single recent study, their full histologic spectrum, detailed immunophenotype, and association with classic pseudomyxoma peritonei (PMP) have not been fully studied.
  • The morphologic, immunohistochemical, and clinical features of 42 patients with mucinous epithelial tumors arising in association with mature ovarian teratomas were evaluated.
  • Tumor size ranged from 5.5 to greater than 200 cm.
  • Most teratoma-associated mucinous tumors were unilateral, although 1 patient harbored bilateral mucinous tumors in association with bilateral teratomas.
  • Using the 2003 World Health Organization criteria for ovarian intestinal type mucinous neoplasms, 17 (40%) were classified as mucinous cystadenoma, 16 (38%) as intestinal-type mucinous epithelial neoplasm of low malignant potential (IM-LMP), 4 (10%) as intraepithelial carcinoma (IEC), and 5 (12%) as invasive mucinous carcinoma.
  • We report that a significant proportion of mucinous tumors associated with mature ovarian teratomas present with clinical PMP, which in most cases is associated with IM-LMP.
  • Pseudomyxoma ovarii is common in this setting, particularly in tumors with IM-LMP histology, but pseudomyxoma ovarii is not predictive of PMP.
  • Ovarian teratoma-associated benign and IM-LMP mucinous neoplasms with microscopic peritoneal low-grade mucinous epithelium do not seem to be at significant risk for intra-abdominal recurrence, but numbers are few and follow-up is limited.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology. Teratoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Female. Humans. Middle Aged. Mucins / metabolism. Neoplasms, Multiple Primary

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18344868.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


87. Kara C, Kutlu AO, Tosun MS, Apaydin S, Senel F: Sertoli cell tumor causing prepubertal gynecomastia in a boy with peutz-jeghers syndrome: the outcome of 1-year treatment with the aromatase inhibitor testolactone. Horm Res; 2005;63(5):252-6
Hazardous Substances Data Bank. TESTOLACTONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sertoli cell tumor causing prepubertal gynecomastia in a boy with peutz-jeghers syndrome: the outcome of 1-year treatment with the aromatase inhibitor testolactone.
  • Peutz-Jeghers syndrome (PJS) is a rare disorder characterized by benign intestinal hamartomatous polyps and mucocutaneous pigmentation, and with an increased risk for intestinal and extra-intestinal neoplasms.
  • Sertoli cell tumors in boys with PJS have been increasingly recognized as a cause of prepubertal gynecomastia.
  • We report on a 7.25-year-old boy with PJS, bilateral gynecomastia, Sertoli cell tumor and nephrocalcinosis, and present the outcome of 1-year treatment with the aromatase inhibitor testolactone.
  • Histopathological examination was consistent with Sertoli cell tumors.
  • [MeSH-major] Aromatase Inhibitors / therapeutic use. Gynecomastia / complications. Peutz-Jeghers Syndrome / complications. Sertoli Cell Tumor / complications. Testicular Neoplasms / complications. Testolactone / therapeutic use

  • Genetic Alliance. consumer health - Peutz Jeghers syndrome.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947469.001).
  • [ISSN] 0301-0163
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 6J9BLA949Q / Testolactone
  •  go-up   go-down


88. Nahal A, Meterissian S: Lipoleiomyosarcoma of the rectosigmoid colon: a unique site for a rare variant of liposarcoma. Am J Clin Oncol; 2009 Aug;32(4):353-5
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Soft tissue tumors with dual adipocytic and smooth muscle differentiation are generally rare with most being benign.
  • RESULTS: Based on the literature, lipoleiomyosarcomas favor body cavities and visceral sites although an occurrence in the intestine has been reported.
  • CONCLUSIONS: This is the first reported case of an intestinal lipoleiomyosarcoma.
  • [MeSH-major] Leiomyosarcoma / pathology. Liposarcoma / pathology. Neoplasm Invasiveness / pathology. Rectal Neoplasms / pathology. Sigmoid Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Colectomy / methods. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Laparotomy / methods. Middle Aged. Neoplasm Staging. Pelvic Pain / diagnosis. Pelvic Pain / etiology. Radiotherapy, Adjuvant. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19363435.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


89. Zurac S, Micu G, Bastian A, Grămadă E, Lavric L, Andrei R, Stăniceanu F, Voiosu R, Croitoru A: Malignancy and overdiagnosis of malignancy in Peutz Jeghers polyposis. Rom J Intern Med; 2008;46(2):179-84
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Peutz Jeghers (PJ) polyps are rare hamartomatous tumors of the gastrointestinal tract frequently associated with skin and mucosal pigmentation.
  • Despite their benign nature there is a certain increased risk of progression to malignancy in some cases, justifying a sustained follow-up of the patients.
  • Two of these cases were related (mother and daughter); both of them were operated in another hospital for small bowel tumors with a subsequent diagnosis of adenocarcinoma.
  • The daughter (28 years old) was referred to our hospital for endoscopic follow-up; a small polyp of the transverse large bowel was excised by colonoscopy with a histopathologic diagnosis of PJ polyp; a careful histopathologic reevaluation of both specimens of enterectomy (slides and paraffin blocks) revealed an overdiagnosis of cancer due to the epithelial cystic dilatation and pseudoinvasion in both patients.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Intestinal Neoplasms / pathology. Intestinal Polyps / pathology. Peutz-Jeghers Syndrome / diagnosis. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19284092.001).
  • [ISSN] 1220-4749
  • [Journal-full-title] Romanian journal of internal medicine = Revue roumaine de médecine interne
  • [ISO-abbreviation] Rom J Intern Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


90. Nonose R, Priolli DG, Cardinalli IA, Máximo FR, Galvão PS, Martinez CA: Epithelioid hemangioma of the colon: a case report. Sao Paulo Med J; 2008 Sep;126(5):294-6
MedlinePlus Health Information. consumer health - Birthmarks.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Epithelioid hemangioma or angiolymphoid hyperplasia with eosinophilia is an uncommon benign vascular neoplasm that is usually located on the face or neck.
  • Two months after the condition started, she began to present changes in her intestinal habit, with evacuations containing blood and mucus and a weight loss of 4 kg over this period.
  • Neoplasia of the colon was clinically suspected and she underwent colonoscopy.
  • It occupied 80% of the intestinal lumen.
  • A biopsy collected during the examination suggested a diagnosis of neoplasia of vascular origin.
  • Despite the rarity of neoplasia of vascular origin, this possibility should be considered in the differential diagnosis for colorectal tumors.
  • [MeSH-major] Angiolymphoid Hyperplasia with Eosinophilia / pathology. Colon / pathology. Hemangioma / pathology. Sigmoid Neoplasms / pathology

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19099166.001).
  • [ISSN] 1806-9460
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


91. Jwo SC, Chien RN, Chao TC, Chen HY, Lin CY: Clinicopathological features, surgical management, and disease outcome of perforated gastric cancer. J Surg Oncol; 2005 Sep 15;91(4):219-25
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Disease outcomes were analyzed in-depth based on tumor stage, depth of tumor invasion, operative curability, and three treatment groups.
  • The remaining five patients were misdiagnosed as having benign gastric perforation and underwent local surgery; these patients were assigned to Group 3.
  • The survival rates for Stage I disease (P = 0.0342), T1/T2 tumors (P = 0.0342), and curative resection (P = 0.0012) significantly exceeded those of Stage III/IV, T3/T4 tumors, and non-curative resection.
  • [MeSH-major] Gastrectomy. Intestinal Perforation / etiology. Stomach / injuries. Stomach Neoplasms / complications. Stomach Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Palliative Care. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16121341.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Lee SH, Lee DS, You IY, Jeon WJ, Park SM, Youn SJ, Choi JW, Sung R: [Histopathologic analysis of adenoma and adenoma-related lesions of the gallbladder]. Korean J Gastroenterol; 2010 Feb;55(2):119-26
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Among 1,847 cholecystectomized specimens, 63 specimens from 26 benign adenomas, 9 carcinomas in situ (CIS), and 28 invasive carcinomas were selected.
  • A pathologist reviewed all specimens and selected benign adenomas, CIS in the adenoma, and adenoma residue in invasive carcinomas.
  • Adenomas and adenoma-related lesions were classified according to morphology (tubular, tubulopapillary, and papillary) and the consisting epithelium (biliary, pyloric metaplasia, and intestinal metaplasia).
  • The age and the size of the benign adenomas and carcinomas in the adenoma were also compared.
  • All eight carcinomas arising in the adenoma were well-differentiated solitary tumors.
  • The diameters of the carcinomas in the adenoma were, on average, larger than that of the benign adenomas (1.8 cm vs. 0.9 cm, p=0.01).
  • The patients with carcinomas in the adenoma were, on average, older than those with benign adenomas, although the difference was insignificant (57 years vs. 47 years, p=0.09).
  • The morphology and consisting epithelium did not differ between the benign adenomas and carcinomas in the adenoma.
  • [MeSH-major] Adenoma / pathology. Gallbladder Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Carcinoma / epidemiology. Carcinoma / pathology. Carcinoma / surgery. Cell Transformation, Neoplastic. Cholecystectomy. Cystadenoma / epidemiology. Cystadenoma / pathology. Cystadenoma / surgery. Female. Gallstones / complications. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20168058.001).
  • [ISSN] 2233-6869
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


93. Emanuel P, Qin L, Harpaz N: Calcifying fibrous tumor of small intestine. Ann Diagn Pathol; 2008 Apr;12(2):138-41
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcifying fibrous tumor of small intestine.
  • Calcifying fibrous tumor (CFT) is a rare benign tumor with a predilection for children and young adults that usually arises in the subcutaneous and deep soft tissues, pleura, or peritoneum.
  • Calcifying fibrous tumor of the gastrointestinal tract is exceedingly rare and therefore prone to confusion with other spindle cell lesions more commonly encountered in this location.
  • We describe 4 cases of calcifying fibrous tumor arising in the terminal ileum, one of which caused the heretofore unreported complication of intestinal intussusception, and discuss the differential diagnosis with other common and uncommon spindle cell lesions.
  • [MeSH-major] Calcinosis / pathology. Fibroma / pathology. Ileal Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Fibromatosis, Aggressive / diagnosis. Gastrointestinal Stromal Tumors / diagnosis. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18325476.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Sunamak O, Karabicak I, Aydemir I, Aydogan F, Guler E, Cetinkaya S, Korman MU: An intraluminal leiomyoma of the small intestine causing invagination and obstruction: a case report. Mt Sinai J Med; 2006 Dec;73(8):1079-81
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An intraluminal leiomyoma of the small intestine causing invagination and obstruction: a case report.
  • Leiomyomas are mostly of benign character and are rarely seen in the gastrointestinal (GI) system.
  • They represent one subgroup of a group of tumors known as gastrointestinal stromal tumors (GIST).
  • Although rarely seen, they are symptomatic tumors, and they comprise 20-30 percent of all benign GI tumors.
  • This is a case report of intestinal leiomyoma in a patient who was suffering with GI obstruction for more than 5 months.
  • The tumor was discovered only after the appearance of intestinal obstruction.
  • [MeSH-major] Gastrointestinal Stromal Tumors / complications. Ileal Neoplasms / complications. Intussusception / etiology. Jejunal Neoplasms / complications. Leiomyoma / complications
  • [MeSH-minor] Aged. Female. Humans. Intestine, Small / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17285198.001).
  • [ISSN] 0027-2507
  • [Journal-full-title] The Mount Sinai journal of medicine, New York
  • [ISO-abbreviation] Mt. Sinai J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Kilicoglu B, Kismet K, Gollu A, Sabuncuoglu MZ, Akkus MA, Serin-Kilicoglu S, Ustun H: Case report: mesenteric schwannoma. Adv Ther; 2006 Sep-Oct;23(5):696-700
Genetic Alliance. consumer health - Schwannoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Schwannomas are benign neurogenic tumors that arise from Schwann cells that line the sheaths of peripheral nerves.
  • The mass was completely excised and included a 4-cm-long intestinal segment that was densely adherent to the mass.
  • Although schwannomas are very rare and generally asymptomatic, these tumors can become quite large and may cause acute abdominal problems such as mechanical bowel obstruction.
  • [MeSH-major] Mesentery. Neurilemmoma / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Humans. Intestinal Obstruction / etiology. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17142203.001).
  • [ISSN] 0741-238X
  • [Journal-full-title] Advances in therapy
  • [ISO-abbreviation] Adv Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Uschuplich V, Hilsenbeck JR, Velasco CR: Paratesticular mucinous cystadenoma arising from an oviduct-like müllerian remnant: a case report and review of the literature. Arch Pathol Lab Med; 2006 Nov;130(11):1715-7
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucinous cystadenomas of the testis and paratestis are extremely rare benign tumors of controversial origin.
  • A few case reports and reviews of testicular and paratesticular mucinous neoplasms resembling ovarian tumors have suggested the possibility of a müllerian origin of these tumors.
  • The current case demonstrates a clear transition from müllerian-type tubal epithelium to intestinal-type mucinous epithelium.
  • [MeSH-major] Cystadenoma, Mucinous / etiology. Cystadenoma, Mucinous / pathology. Mullerian Ducts / pathology. Testicular Neoplasms / etiology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Humans. Immunohistochemistry. Immunophenotyping. Intestinal Mucosa / pathology. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17076537.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 10
  •  go-up   go-down


97. Wrba F: [Gastrointestinal stomal tumours, morphology and molecular pathology]. Wien Med Wochenschr; 2009;159(15-16):383-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastointestinal stromal tumours (GIST) are the most common mesenchymal neoplasms of the digestive tract.
  • GIST are not regarded as benign tumours, and morphological risk assessment is generally recommended according to the NIH consensus adapted from Fletcher et al.
  • Other classifications (Miettinen and Lasota, Joensuu) considering the tumour site and tumour integrity as individual criterion may give different assessment results.
  • In doing so the use of a panel of antibodies is recommended helpful to cover all differential diagnostic relevant possibilities of mesenchymal neoplasms of the digestive tract.
  • [MeSH-major] Gastrointestinal Stromal Tumors / genetics. Gastrointestinal Stromal Tumors / pathology. Proto-Oncogene Proteins c-kit / genetics. Receptor, Platelet-Derived Growth Factor alpha / genetics
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Chloride Channels. DNA Mutational Analysis. Diagnosis, Differential. Gastric Mucosa / pathology. Gastrointestinal Tract / pathology. Humans. Immunohistochemistry. Intestinal Mucosa / pathology. Membrane Proteins / genetics. Mitotic Index. Neoplasm Proteins / genetics. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19696981.001).
  • [ISSN] 1563-258X
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / ANO1 protein, human; 0 / Biomarkers, Tumor; 0 / Chloride Channels; 0 / Membrane Proteins; 0 / Neoplasm Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  • [Number-of-references] 11
  •  go-up   go-down


98. Korsisaari N, Kasman IM, Forrest WF, Pal N, Bai W, Fuh G, Peale FV, Smits R, Ferrara N: Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice. Proc Natl Acad Sci U S A; 2007 Jun 19;104(25):10625-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anti-VEGF-A monoclonal antibodies, in combination with chemotherapy, result in a survival benefit in patients with metastatic colorectal and non-small cell lung cancer, but little is known regarding the impact of anti-VEGF-A therapy on benign or premalignant tumors.
  • The Apc+/min mice have been widely used as a model recapitulating early intestinal adenoma formation.
  • To investigate whether tumor growth in Apc+/min mice is mediated by VEGF-A-dependent angiogenesis, we used two independent approaches to inhibit VEGF-A: monotherapy with a monoclonal antibody (Mab) targeting VEGF-A and genetic deletion of VEGF-A selectively in intestinal epithelial cells.
  • Short-term (3 or 6 weeks) treatment with anti-VEGF-A Mab G6-31 resulted in a nearly complete suppression of adenoma growth throughout the small intestine.
  • Deletion of VEGF-A in intestinal epithelial cells of Apc+/min mice yielded a significant inhibition of tumor growth, albeit of lesser magnitude than that resulting from Mab G6-31 administration.
  • These results establish that inhibition of VEGF-A signaling is sufficient for tumor growth cessation and confers a long-term survival benefit in an intestinal adenoma model.
  • Therefore, VEGF-A inhibition may be a previously uncharacterized strategy for the prevention of the angiogenic switch and growth in intestinal adenomas.
  • [MeSH-minor] Adenoma / blood supply. Adenoma / genetics. Adenoma / immunology. Adenoma / therapy. Animals. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / pharmacology. Gene Deletion. In Situ Hybridization. Intestinal Neoplasms / blood supply. Intestinal Neoplasms / genetics. Intestinal Neoplasms / immunology. Intestinal Neoplasms / therapy. Mice. Mice, Inbred C57BL. Signal Transduction / immunology. Survival Analysis. Time Factors

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5209-18 [10537299.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):316-25 [16507828.001]
  • [Cites] Genes Dev. 2000 Aug 1;14(15):1837-51 [10921899.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5040-4 [11016626.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6253-8 [11103779.001]
  • [Cites] Cancer Lett. 2002 Jan 25;175(2):157-63 [11741743.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):506-11 [11809702.001]
  • [Cites] Dev Dyn. 2002 May;224(1):90-102 [11984877.001]
  • [Cites] Carcinogenesis. 2002 Aug;23(8):1351-9 [12151354.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8 [12177445.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):33275-83 [12065599.001]
  • [Cites] Expert Opin Investig Drugs. 2002 Dec;11(12):1715-36 [12457433.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):391-400 [12750232.001]
  • [Cites] Br J Cancer. 2003 May 6;88(9):1445-52 [12778076.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Curr Biol. 2003 Sep 30;13(19):1721-7 [14521839.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] J Exp Med. 1972 Aug 1;136(2):261-76 [5043412.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Dec;82(24):8488-92 [3909146.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Science. 1992 May 1;256(5057):668-70 [1350108.001]
  • [Cites] Development. 1992 Jul;115(3):717-28 [1425351.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):841-4 [7683111.001]
  • [Cites] J Clin Invest. 1995 Apr;95(4):1789-97 [7535799.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2556-60 [8653697.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Nature. 1997 Apr 17;386(6626):671-4 [9109485.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4267-73 [9331087.001]
  • [Cites] Prostate. 1998 Apr 1;35(1):1-10 [9537593.001]
  • [Cites] Carcinogenesis. 1999 Jan;20(1):51-8 [9934849.001]
  • [Cites] Development. 1999 Mar;126(6):1149-59 [10021335.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4389-400 [15899831.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):967-74 [16355214.001]
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):951-61 [16278208.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):549-60 [16336962.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1710-7 [16685275.001]
  • [Cites] Carcinogenesis. 2006 Oct;27(10):2133-9 [16782971.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3478-83 [17360669.001]
  • [Cites] J Clin Invest. 2000 Jun;105(11):1589-94 [10841517.001]
  • (PMID = 17553957.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC1888576
  •  go-up   go-down


99. Mathew M, Gowri V, Al Hamdani A, Machado L, Rao K, Shabnam S: Cotyledonoid leiomyoma in pregnancy. Obstet Gynecol; 2007 Feb;109(2 Pt2):509-11
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Benign smooth-muscle tumors (leiomyomata) are the most frequent tumors found in the female genital tract.
  • CONCLUSION: Familiarity with benign uterine smooth-muscle tumors with unusual growth patterns by gynecologists and pathologists is essential in avoiding over-treatment.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Leiomyoma / diagnosis. Pregnancy Complications, Neoplastic / diagnosis. Prenatal Diagnosis. Smooth Muscle Tumor / diagnosis

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Prenatal Testing.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17267876.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Mann CM, Bramhall SR, Buckels JA, Taniere P: An unusual case of duodenal obstruction-gangliocytic paraganglioma. J Hepatobiliary Pancreat Surg; 2009;16(4):562-5
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gangliocytic paragangliomas are rare tumors located in the gastrointestinal tract that are considered to be benign.
  • Intraoperatively, the patient was found to have local tumor extension and regional lymph node invasion, and so she underwent a pylorus-preserving pancreaticoduodenectomy, with local lymph node clearance.
  • [MeSH-major] Duodenal Neoplasms / complications. Intestinal Obstruction / etiology. Paraganglioma / complications
  • [MeSH-minor] Adolescent. Endoscopy, Digestive System. Female. Humans. Lymph Nodes / pathology. Neoplasm Invasiveness. Pancreaticoduodenectomy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19517054.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down






Advertisement